| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 interim results example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Infectious Diseases | ||
Phase 2 interim results example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Infectious Diseases | ||
Phase 2 interim results example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Infectious Diseases |
Recent Updates
Recently added Catalysts
Aligos Therapeutics, Inc.$6.62
-0.15 (-2.22%)
D 33Pipeline Score Overvalued Biotech · Clinical
Market Cap
32.49 M
EPS
-8.70
P/E Ratio
-0.6 $
Value Trade
268.89 K
SEC Financials
Q1 2026Dilution Risk
Revenue
2.83 M
R&D Expenses
23.35 M
Operating CF
-23.13 M
Total Assets
64.56 M
Total Liabilities
32.77 M
Equity
31.79 M
D/E Ratio
12,345
-11.25 %
Week
-12.06 %
1 Month
-19.1 %
3 Month
-31.18 %
6 Month
-99.1 %
5 Year
-98.68 %
All Time
Cash Data
Cash Position
54.91 M
Monthly Burn
7.71 M
Runway
5.2 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
109.33 K
52 Week Range
5.01 - 13.69
% held by Insiders
22.49 %
% held by Institutions
44.85 %
Enterprise Value
-18.24 M
Total Shares
5.39 M
Short %
12.74 %
Float Shares
4.81 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aligos Therapeutics, Inc.
461Total events
8Upcoming
68Tier-1 (high impact)
2019 – 2027Coverage
Upcoming catalysts 8
TBD
T2Oral Presentation
Post-treatment data from Phase 1 study to be presented at upcoming scientific meetings
Event history 453
Jul 6, 2026
▲Partnership / LicensePevifoscorvirCorporate
Exclusive license deal of pevifoscorvir sodium in Greater China with Amoytop
chronic hepatitis B virus infectionsource ↗
Jul 6, 2026
▲NMPA PriorityPevifoscorvirEx-US Regulatory
Breakthrough Therapy Designation granted by CDE of NMPA in China
chronic hepatitis B virus infectionsource ↗
Q3 2026
▲Enrollment CompletePevifoscorvirTrial
Completion of enrollment in HBeAg- cohort expected in second half of 2026
chronic hepatitis B virus infectionsource ↗
Q3 2026
◆Interim AnalysisPevifoscorvirTrial
Second interim analysis expected in second half of 2026
chronic hepatitis B virus infectionsource ↗
Q3 2026
◆Trial InitiationALG-170675Trial
Planned entrance of ALG-170675 into clinic in China
chronic HBV infectionsource ↗
May 28, 2026
◆Poster PresentationALG-001075Presentation
Abstract #570: ALG-001075, the parent of pevifoscorvir sodium, exhibits potent in vitro antiviral properties compared to other HBV capsid assembly modulators in clinical development
chronic hepatitis B virus (HBV) infectionsource ↗
May 28, 2026
◆Poster PresentationALG-170674Presentation
Abstract #587: The potentially best-in-class HBV ASO ALG-170674 demonstrates additive to synergistic antiviral activities when combined with other anti-HBV modalities
chronic hepatitis B virus (HBV) infectionsource ↗
May 28, 2026
◆Poster PresentationPresentation
Abstract #606: Antisense oligonucleotide-based strategy to target hepatitis delta virus infections
hepatitis delta virus infectionssource ↗
May 28, 2026
◆Poster PresentationALG-093940Presentation
Abstract #620: Preclinical characterization of ALG-093940, a potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor for the treatment of chronic hepatitis B infection and liver cancer
chronic hepatitis B infection and liver cancersource ↗
May 28, 2026
▲Oral PresentationALG-001075Presentation
Potent and durable off-treatment reduction of HBsAg levels and cccDNA-derived transcripts by CAM-E ALG-001075 in cell-based experiments
chronic hepatitis B virus (HBV) infectionsource ↗
May 28, 2026
▲Oral PresentationALG-170675Presentation
The potentially best-in-class HBV ASO ALG-170674 demonstrates additive to synergistic antiviral activities when combined with other anti-HBV modalities
chronic hepatitis B virus (HBV) infectionsource ↗
Drug Pipeline Intelligence
D33
Pipeline Score $11M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.3x
rNPV / MCap Top 44%
Micro Cap (rank 511 of 911)
Percentile RankAligos Therapeutics, Inc. faces pipeline headwinds (33/100), with $793M risk-adjusted pipeline value, led by ALG-055009 in NASH (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALG-055009 Small molecule | NASH | Phase 2 | NCT06342947 | 21% | $337M | COMPLETED | 102 | - | - | Sep 9, 2024 | - | Feb 17, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
pevifoscorvir sodium BreakthroughFast Track | chronic HBV infection | Phase 1 | 2026-05-27 | 40% of HBeAg+ participants achieved significant reductions in HBsAg; 4 (44%) maintained HBV DNA levels below the lower limit of quantification (LLOQ; 10 IU/mL); 40% (4/10) achieved HBsAg <3,000 IU/mL at 48 weeks Read More | Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 Read More | |
pevifoscorvir sodium BreakthroughFast Track | chronic HBV infection | Phase 1 | 2026-05-27 | 40% of HBeAg+ participants achieved significant reductions in HBsAg; 4 (44%) maintained HBV DNA levels below the lower limit of quantification (LLOQ; 10 IU/mL); 40% (4/10) achieved HBsAg <3,000 IU/mL at 48 weeks Read More | Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 Read More | |
pevifoscorvir sodium BreakthroughFast Track | chronic HBV infection | Phase 1 | 2026-05-27 | 40% of HBeAg+ participants achieved significant reductions in HBsAg; 4 (44%) maintained HBV DNA levels below the lower limit of quantification (LLOQ; 10 IU/mL); 40% (4/10) achieved HBsAg <3,000 IU/mL at 48 weeks Read More | Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ALGS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ALGS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ALGSAligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Aligos Therapeutics has secured a $25 million upfront payment from Xiamen Amoytop Biotech for the exclusive licensing of pevifoscorvir sodium in Greater China. The drug has also received Breakthrough Therapy Designation from China's regulatory authority, facilitating priority review for its New Drug Application. Aligos stands to gain up to $420 million in milestone payments and retains rights in other key markets.
Read more →ALGS▼ -6.1%on this news
Synergistic fat mass loss in diet-induced obese mice when thyroid hormone receptor-β agonist ALG-055009 was administered in combination with incretin receptor agonists
The study highlights the synergistic effects of the thyroid hormone receptor-β agonist ALG-055009 when combined with incretin receptor agonists in promoting fat mass loss in diet-induced obese mice. This combination therapy could represent a novel approach to treating obesity. The findings suggest a promising avenue for further research and potential clinical applications.
Read more →ALGSALG-001075, the parent of pevifoscorvir sodium, exhibits potent in vitro antiviral properties compared to other HBV capsid assembly modulators in clinical development
ALG-001075, a promising antiviral agent, has demonstrated strong in vitro efficacy against HBV compared to other drugs in development. This positions it favorably in the ongoing fight against chronic HBV infection. The article highlights its potential as a significant player in the treatment landscape.
Read more →ALGSPotent and durable off-treatment reduction of HBsAg levels and cccDNA-derived transcripts by the CAM-E ALG-001075 in cell-based experiments
The article discusses the promising results of the CAM-E ALG-001075 in reducing HBsAg levels and cccDNA-derived transcripts in cell-based experiments. The treatment shows a potent and durable effect, indicating its potential as a therapeutic option for chronic HBV infection. These findings may pave the way for further clinical applications.
Read more →ALGSAntisense oligonucleotide-based strategy to target hepatitis delta virus infections
The article discusses an antisense oligonucleotide-based strategy aimed at targeting hepatitis delta virus infections. It provides an overview of the company's management, pipeline, and clinical trials related to chronic HBV infection. The content primarily focuses on corporate governance and investor-related information without detailed insights into the scientific advancements or clinical results.
Read more →ALGSDiscovery of novel HDV entry inhibitors with selectivity over bile acid inhibition
The article discusses the discovery of novel entry inhibitors for Hepatitis D Virus (HDV) that exhibit selectivity over bile acid inhibition. This development could have significant implications for the treatment of chronic HBV infection. However, specific details regarding the inhibitors' efficacy or clinical trial results are not provided.
Read more →ALGSPreclinical characterization of ALG-093940, a potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor for the treatment of chronic hepatitis B infection and liver cancer
The article discusses the preclinical characterization of ALG-093940, a small molecule inhibitor targeting PD-1/PD-L1 pathways. This compound is being developed for the treatment of chronic hepatitis B infection and liver cancer. Its oral bioavailability may improve patient adherence to treatment regimens.
Read more →ALGSThe potentially best-in-class HBV ASO ALG-170674 demonstrates additive to synergistic antiviral activities when combined with other anti-HBV modalities
The article discusses ALG-170674, a promising HBV ASO that exhibits strong antiviral effects when used in combination with other treatments. Its potential as a best-in-class therapy for chronic HBV infection is highlighted, emphasizing its additive and synergistic properties. The findings suggest a significant advancement in HBV treatment options.
Read more →ALGSPopulation pharmacokinetics of pevifoscorvir sodium (ALG-000184) in healthy participants and participants with chronic hepatitis B in support of phase 2 dose selection
The article discusses the population pharmacokinetics of pevifoscorvir sodium (ALG-000184) in healthy participants and those with chronic hepatitis B. It aims to support the selection of doses for phase 2 clinical trials. The focus is on the drug's performance and safety profile in different participant groups.
Read more →ALGSSustained reduction of HBV antigen levels at ≥6 months follow-up in HBeAg-positive participants with chronic hepatitis B infection after 96 weeks of 300 mg pevifoscorvir sodium monotherapy
The article discusses the promising results of a study on pevifoscorvir sodium monotherapy for chronic hepatitis B infection. Participants showed a sustained reduction in HBV antigen levels after 96 weeks of treatment. This suggests that the drug may be an effective option for HBeAg-positive patients. Further research may be needed to confirm these findings.
Read more →ALGSPevifoscorvir sodium demonstrated profound antiviral activity in untreated HBeAg+ subjects, regardless of baseline ALT level
Pevifoscorvir sodium has demonstrated significant antiviral activity in untreated HBeAg+ subjects, showing effectiveness regardless of baseline ALT levels. This finding suggests a promising potential for the treatment of chronic HBV infection. The results highlight the drug's capability to address a critical need in managing hepatitis B.
Read more →ALGSAligos Therapeutics Presents Positive Data at the EASL Congress 2026
Aligos Therapeutics presented promising data at the EASL Congress 2026, highlighting the efficacy of pevifoscorvir sodium in reducing the cccDNA reservoir in chronic HBV patients. Notably, 40% of participants achieved significant reductions in HBsAg, suggesting eligibility for functional cure treatments. The combination of pevifoscorvir sodium and antisense oligonucleotide ALG-170675 showed synergistic effects, indicating a potential shift in treatment standards for chronic HBV infection.
Read more →ALGSCo-Administration of Thyroid Hormone Receptor-beta Agonist ALG-055009 and Incretin Receptor Agonists Leads to Synergistic Weight Loss and Modulation of Molecular Pathways Underlying Adipocyte Dysfunction in Diet-Induced Obese Mice
The study discusses the co-administration of the thyroid hormone receptor-beta agonist ALG-055009 with incretin receptor agonists, demonstrating a synergistic effect on weight loss in diet-induced obese mice. This combination also modulates molecular pathways linked to adipocyte dysfunction, suggesting a promising avenue for obesity treatment. The findings contribute to understanding obesity management strategies.
Read more →ALGSAligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
Aligos Therapeutics has announced that ten of its abstracts have been accepted for poster presentations at the EASL Congress 2026 in Barcelona. The presentations will focus on their innovative therapies targeting chronic hepatitis B and metabolic dysfunction-associated steatohepatitis. This recognition highlights Aligos' commitment to advancing treatment options in liver diseases.
Read more →ALGS▼ -5.3%on this news
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
Aligos Therapeutics has reported its business progress and financial results for Q1 2026, highlighting the Fast Track Designation for its drug, pevifoscorvir sodium, aimed at chronic HBV infection. The interim analysis of the B-SUPREME study indicated positive results, with a recommendation to increase participant numbers to improve the study's success rate. However, the company also reported a significant net loss compared to the previous year due to rising R&D expenditures. Aligos continues to collaborate with Amoytop for developments in Greater China, which could enhance its market presence.
Read more →ALGSAligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
Aligos Therapeutics, Inc. has announced it will report its first quarter 2026 financial results on May 7, 2026. The company is focused on improving patient outcomes through its development of best-in-class therapies aimed at liver and viral diseases, addressing conditions like chronic hepatitis B and metabolic disorders. However, the press release also emphasizes the inherent risks associated with drug development and clinical trials, which may affect actual results compared to forward-looking statements. Investors are advised to refer to Aligos' annual report for detailed risks.
Read more →ALGSCapsid Assembly Modulator ALG-001075 Prevents CCCDNA Formation and HBV DNA Integration in Vitro
The article discusses the efficacy of Capsid Assembly Modulator ALG-001075 in preventing CCCDNA formation and HBV DNA integration in vitro. This development could represent a significant advancement in the treatment of chronic HBV infection. The findings suggest that ALG-001075 may play a crucial role in future therapeutic strategies against HBV.
Read more →ALGSALG-098340, an Investigational, Potent, Pan-Coronavirus 3CLPRO Inhibitor for Pandemic Preparedness
The article discusses ALG-098340, an investigational drug designed to inhibit the 3CLPRO enzyme across various coronaviruses. This development is part of efforts to enhance pandemic preparedness. The drug's potential effectiveness against multiple strains highlights its significance in addressing future viral outbreaks.
Read more →ALGSAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics, Inc. has announced the granting of stock options amounting to 10,700 shares to newly hired employees as part of an Inducement Grant under Nasdaq Listing Rule 5635(c)(4). This move aims to attract talent as the company focuses on developing therapies for liver and viral diseases. The stock options will vest over four years, reflecting a commitment to employee retention and growth in the clinical stage biopharmaceutical field. However, the announcement includes forward-looking statements that highlight potential risks and uncertainties related to drug development and regulatory processes.
Read more →ALGS▼ -12.8%on this news
Preclinical Characterization of ALG-094295, a Highly Potent and Orally Bioavailable Small Molecule PD-1/PD-L1 Inhibitor Targeting Dimerization, Internalization and Degradation of PD-L1
The article discusses the preclinical characterization of ALG-094295, a new small molecule PD-1/PD-L1 inhibitor. This compound is noted for its high potency and oral bioavailability, which could improve treatment adherence. It specifically targets the dimerization, internalization, and degradation of PD-L1, potentially offering a novel approach in cancer therapy.
Read more →ALGS▼ -12.8%on this news
Preclinical Characterization of ALG-093940, a Potent and Orally Bioavailable Small Molecule PD-1/PD-L1 Inhibitor Targeting PD-L1 Dimerization, Internalization and Degradation
The article discusses the preclinical characterization of ALG-093940, a small molecule designed to inhibit PD-1/PD-L1 interactions. This compound targets PD-L1 dimerization, internalization, and degradation, suggesting a novel approach to cancer immunotherapy. Its oral bioavailability could improve treatment adherence among patients.
Read more →ALGSAligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Aligos Therapeutics has entered an exclusive licensing agreement with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium for chronic hepatitis B in Greater China. Aligos will receive an upfront payment of $25 million and could earn up to $420 million in milestones. The partnership aims to leverage Amoytop's established market presence to enhance the drug's development and regulatory success.
Read more →ALGS▼ -15.1%on this news· ran to -26% by day 3shared move
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
Aligos Therapeutics announced positive interim results from the Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic hepatitis B virus infection. The independent Data Safety Monitoring Board recommended increasing the sample size for better statistical power. Additionally, the FDA granted Fast Track Designation to the drug, facilitating its development and review process.
Read more →ALGSAligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
Aligos Therapeutics reported progress in its clinical trials and financial results for 2025. The Phase 2 B-SUPREME study of pevifoscorvir sodium has completed enrollment for the HBeAg- cohort, with ongoing enrollment for HBeAg+ participants. The company also advanced ALG-170675 into IND-enabling studies and appointed James Hassard as Chief Commercial Officer. Financially, Aligos showed reduced net losses compared to 2024.
Read more →ALGS▲ +8.1%on this news
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
Aligos Therapeutics, a clinical-stage biotechnology company, will announce its fourth quarter 2025 financial results on March 5, 2026. The company aims to improve patient outcomes through innovative therapies for liver and viral diseases. Aligos has a pipeline targeting chronic hepatitis B, metabolic dysfunction-associated steatohepatitis, obesity, and coronaviruses.
Read more →ALGSPharmacokinetics of ALG-097558, a Pan-Coronavirus 3CL-Pro Inhibitor, in Renal and Hepatic Impairment
The article discusses the pharmacokinetics of ALG-097558, a pan-coronavirus 3CL-pro inhibitor, particularly in the context of renal and hepatic impairment. It highlights the drug's potential applications and the importance of understanding its behavior in patients with these conditions. However, specific details on study results or implications are not provided.
Read more →ALGSHigh Viral Suppression in Chronic HBV Infection Subjects with Pevifoscorvir Sodium Monotherapy
The article discusses the positive outcomes of Pevifoscorvir sodium monotherapy in subjects with chronic HBV infection, highlighting significant viral suppression. This development is crucial for patients suffering from this condition, indicating a potential advancement in treatment options. The results suggest a favorable response to the therapy, marking a step forward in managing chronic HBV.
Read more →ALGSAligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
Aligos Therapeutics presented promising data at the Conference on Retroviruses and Opportunistic Infections (CROI), focusing on two key projects. The Phase 1 study of pevifoscorvir sodium demonstrated high viral suppression in chronic hepatitis B virus (HBV) patients. Additionally, data on ALG-097558, a pan-coronavirus protease inhibitor, was showcased, highlighting its pharmacokinetics in patients with renal and hepatic impairment.
Read more →ALGS▼ -8.2%on this news
Structural basis for pan-coronavirus inhibition of 3CL protease
The article provides an overview of Aligos Therapeutics, detailing its management structure, clinical trials, and investor relations. It highlights the company's focus on chronic HBV infection and MASH, alongside various resources available for investors and patients. However, specific details about recent developments or breakthroughs are not included.
Read more →ALGSAligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
Aligos Therapeutics has provided an update on its Phase 2 B-SUPREME study for pevifoscorvir sodium in chronic hepatitis B patients. Currently, 144 subjects are enrolled, with interim analyses planned for 2026. The company remains optimistic about the drug's potential, with topline data expected in 2027. However, a leadership change has occurred with the resignation of the Chief Medical Officer.
Read more →ALGSALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial
The article discusses the phase 1, multicentre, randomized, dose escalation trial of ALG-000184 (pevifoscorvir sodium) for participants with chronic HBV infection. It outlines the study's design and objectives but does not provide specific results or outcomes. The focus is on the clinical trial's framework rather than findings.
Read more →ALGS▲ +6.1%on this newsshared move
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer
Aligos Therapeutics has appointed James Hassard as Executive Vice President and Chief Commercial Officer. He will lead the company's global commercial capabilities as they progress towards late-stage development of pevifoscorvir sodium. Hassard brings extensive experience from previous roles in various pharmaceutical companies, enhancing Aligos's potential to deliver better patient outcomes.
Read more →ALGSAligos Therapeutics Presents Positive Data at HEP-DART 2025
Aligos Therapeutics presented positive data at the HEP-DART 2025 Meeting, showcasing the Phase 1 study results for pevifoscorvir sodium in chronic HBV infection. Additionally, new data on ALG-055009 indicated synergistic effects when combined with incretin receptor agonists for weight loss. The company emphasized its dedication to developing innovative therapies for liver and viral diseases.
Read more →ALGSRapid, profound and durable antiviral effects in treatment-naïve or currently-not-treated subjects with chronic hepatitis B virus infection that received 300 mg pevifoscorvir sodium monotherapy for 96 weeks
The study reports significant antiviral effects from 300 mg pevifoscorvir sodium monotherapy in treatment-naïve or currently untreated patients with chronic hepatitis B virus infection. The treatment demonstrated rapid and durable results over a 96-week period, indicating its potential as a viable therapeutic option for this patient population.
Read more →ALGSAn antisense oligonucleotide strategy targeting the Hepatitis Delta Virus
The article provides an overview of Aligos Therapeutics, focusing on their antisense oligonucleotide strategy aimed at targeting the Hepatitis Delta Virus. It includes sections about the company's management, pipeline, clinical trials, and investor relations. However, it lacks specific details about the strategy's effectiveness or recent developments.
Read more →ALGSExplorations Towards the Selection of a Potential Best-in-Class HBV ASO
The article provides an overview of Aligos Therapeutics, focusing on their efforts towards developing a best-in-class antisense oligonucleotide (ASO) for chronic HBV infection. It outlines the company's management structure, pipeline, and various resources available for investors and patients. However, it lacks specific details on recent developments or findings related to the HBV ASO.
Read more →ALGS▲ +11.5%on this news
A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants
A Phase 1 study is being conducted to evaluate the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium) in healthy participants. This novel Class E capsid assembly modulator targets chronic HBV infection. The trial's results could provide insights into the drug's potential effectiveness and safety profile.
Read more →ALGSAligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
Aligos Therapeutics presented promising data at The Liver Meeting 2025, showcasing the effectiveness of pevifoscorvir sodium for chronic hepatitis B virus (HBV) infection. The data revealed high rates of HBV DNA suppression and a favorable safety profile over 96 weeks of treatment. The findings suggest that pevifoscorvir sodium may significantly impact the HBV lifecycle, reinforcing its potential as a first-line therapy.
Read more →ALGSOral Once-Daily 300 mg ALG-000184, a Novel Capsid Assembly Modulator Demonstrates potent suppression of HBV DNA in Treatment-Naive or Currently-not-treated Subjects with Chronic HBV
The article discusses the promising results of ALG-000184, an oral capsid assembly modulator, which has shown significant efficacy in suppressing HBV DNA levels in patients with chronic hepatitis B virus infection. This treatment is particularly noteworthy for both treatment-naive individuals and those not currently receiving treatment. The findings suggest a potential new avenue for managing chronic HBV.
Read more →ALGSTwo Pre-clinical Short Interfering RNA Molecules Targeting Human HSD17beta13 for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
The article discusses the development of two pre-clinical short interfering RNA molecules aimed at targeting human HSD17beta13. This approach is intended for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a condition linked to chronic HBV infection. The research highlights the potential of these molecules in addressing metabolic disorders effectively.
Read more →ALGSLead Optimization and Selection of a Potential Best-in-Class HBV ASO
The article provides an overview of Aligos Therapeutics, focusing on their lead optimization and selection process for a potential best-in-class antisense oligonucleotide (ASO) targeting chronic HBV infection. It includes information about the company's management, pipeline, and clinical trials. However, specific details about the ASO's efficacy or development status are not provided.
Read more →ALGSCAM-E and CAM-A Compounds Differentially Affect Phosphorylated and Non-Phosphorylated Hepatitis B Core Protein In Vitro
The article discusses the differential effects of CAM-E and CAM-A compounds on phosphorylated and non-phosphorylated Hepatitis B core protein in vitro. It provides an overview of the compounds' impact on chronic HBV infection, but lacks specific results or conclusions from the research.
Read more →ALGSDifferentiation of HBV capsid assembly modulators based on stabilization of core protein oligomerization and residence time
The article discusses the differentiation of HBV capsid assembly modulators, focusing on the stabilization of core protein oligomerization and their residence time. It highlights the importance of these factors in the context of chronic HBV infection and potential therapeutic strategies. However, specific details on findings or implications are not provided.
Read more →ALGSCapsid Assembly Modulator ALG-001075 Binds and Directly Targets HBeAg
The article provides an overview of the company ALGS, detailing its management, board of directors, and pipeline related to chronic HBV infection. It highlights various aspects such as clinical trials, investor relations, and governance. However, it lacks specific news or developments regarding the capsid assembly modulator ALG-001075.
Read more →ALGSCapsid Assembly Modulator ALG-001075 Prevents cccDNA Formation and HBV DNA Integration In Vitro
The article discusses the promising effects of ALG-001075, a capsid assembly modulator, in preventing the formation of cccDNA and HBV DNA integration in vitro. This suggests a potential therapeutic avenue for chronic HBV infection. The findings could lead to advancements in treatment strategies for affected patients.
Read more →ALGSSustained Reduction of HBV Antigen Levels During the 8-Week Follow-up Period in Treatment Naïve (TN) or Currently-Not-Treated (CNT) HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection After 96-Week 300 mg ALG-000184
The article discusses the positive results of a study on ALG-000184, which showed sustained reductions in HBV antigen levels during an 8-week follow-up in treatment-naïve and currently-not-treated HBeAg-positive subjects with chronic hepatitis B. This suggests potential effectiveness in managing chronic HBV infections.
Read more →ALGSAligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
Aligos Therapeutics reported its third quarter 2025 financial results, highlighting progress in its Phase 2 B-SUPREME study of pevifoscorvir sodium. The company has $99.1 million in cash, sufficient to fund operations into Q3 2026. Despite a net loss increase, Aligos remains optimistic about its pipeline, including ALG-055009 for obesity and MASH.
Read more →ALGSAligos Therapeutics to Present at Upcoming Investor Conferences
Aligos Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two investor conferences: the Jefferies London Healthcare Conference and the Piper Sandler 37th Annual Healthcare Conference. Management will present details about their innovative therapies aimed at liver and viral diseases. Webcasts of the presentations will be available for replay on their website.
Read more →ALGSAligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
Aligos Therapeutics, a clinical stage biotechnology company, will announce its third quarter 2025 financial results on November 6, 2025. The company is dedicated to developing therapies for liver and viral diseases, including chronic hepatitis B. Aligos emphasizes a science-driven approach and has a pipeline addressing significant medical needs.
Read more →ALGSAligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
Aligos Therapeutics has received approval from the USAN Council for the nonproprietary name pevifoscorvir sodium for its investigational drug ALG-000184, aimed at treating chronic hepatitis B virus infection. This marks a significant milestone for the company as it progresses in its Phase 2 B-SUPREME study. The drug has shown positive results in earlier trials, indicating its potential as a leading treatment option.
Read more →ALGSAligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference
Aligos Therapeutics will present at the H.C. Wainwright Liver Disease Conference on October 21-22, 2025. The presentation will be accessible via a webcast on their website, with a replay available for 30 days. Aligos is dedicated to developing therapies for liver and viral diseases, addressing high unmet medical needs.
Read more →ALGSAligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025
Aligos Therapeutics announced the acceptance of eight abstracts for presentation at The Liver Meeting 2025, including one oral presentation. The abstracts focus on innovative therapies for chronic hepatitis B, showcasing the company's commitment to addressing unmet medical needs. The event is scheduled for November 7-11, 2025, in Washington, D.C.
Read more →ALGSA multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG-055009, a novel thyroid hormone receptor beta (THR-β) agonist for metabolic dysfunction-associated steatohepatitis (MASH), in healthy participants
A phase 1 study is underway to assess the safety, pharmacodynamics, and pharmacokinetics of ALG-055009, a new thyroid hormone receptor beta agonist targeting metabolic dysfunction-associated steatohepatitis (MASH). The trial involves healthy participants and aims to provide insights into the drug's potential benefits for treating MASH.
Read more →ALGS▼ -6.3%on this news
The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experiments
The article discusses the promising results of the CAM-E ALG-001075 in preclinical trials, demonstrating its ability to significantly reduce HBV cccDNA levels. This advancement could lead to improved treatment options for patients suffering from chronic HBV infection. The findings highlight the potential of ALG-001075 in addressing a critical need in hepatitis B management.
Read more →ALGSA Syrian hamster model of persistent HDV infection
The article discusses a Syrian hamster model used for studying persistent Hepatitis D Virus (HDV) infection. It highlights the relevance of this model in understanding chronic HBV infection and its implications for clinical trials. The content is primarily focused on the scientific aspects without providing specific outcomes or results.
Read more →ALGSDifferential impact of CAM-E and CAM-A on hepatitis B core protein phosphorylation states in vitro
The article discusses the differential impact of CAM-E and CAM-A on the phosphorylation states of hepatitis B core protein in vitro. It highlights the significance of these findings in understanding chronic HBV infection. However, the article lacks specific details on experimental results or implications for treatment.
Read more →ALGSCapsid assembly modulators bind and directly target HBeAg
The article discusses the role of capsid assembly modulators in targeting HBeAg for chronic HBV infection. It provides an overview of the company's management, pipeline, and clinical trials related to the treatment of HBV. The information is primarily structured as a corporate overview without specific details on recent developments or results.
Read more →ALGSPML nuclear bodies store aggregated HBc and reduce CAM-induced apoptosis in HBc-expressing cells
The article provides an overview of Aligos Therapeutics, including its management, pipeline, and clinical trials related to chronic HBV infection. It highlights the company's focus on developing treatments and its investor relations. However, no specific news event or breakthrough is detailed in the text.
Read more →ALGSAligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
Aligos Therapeutics announced six preclinical presentations at the 2025 International HBV Meeting, highlighting advancements in therapies for liver and viral diseases. Notably, the presentations include findings on ALG-000184's effectiveness in reducing HBV cccDNA and a novel antisense oligonucleotide strategy targeting hepatitis delta virus. The event underscores Aligos' commitment to innovation in treating chronic HBV and HDV infections.
Read more →ALGSAligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Aligos Therapeutics, a clinical-stage biopharmaceutical company, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The presentation will be accessible via a webcast on their website, with a replay available for 30 days. Aligos aims to develop therapies for liver and viral diseases, addressing significant unmet medical needs.
Read more →ALGSAligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
Aligos Therapeutics has announced the commencement of dosing in the Phase 2 B-SUPREME study of its investigational drug ALG-000184 for chronic hepatitis B virus (HBV) infection. This trial will evaluate the efficacy and safety of ALG-000184 compared to tenofovir disoproxil fumarate. The study involves approximately 200 subjects and aims to provide interim data in 2026, with topline results expected by 2027. The drug has previously shown promising antiviral activity and has a clear regulatory path ahead, signaling potential advancements in treatment for chronic HBV infection.
Read more →ALGSAligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
Aligos Therapeutics, Inc. has reported recent business developments and financial results for Q2 2025. The company has initiated the Phase 2 B-SUPREME study for its lead candidate, ALG-000184, aimed at treating chronic HBV infection, with positive early data suggesting its efficacy. Financially, Aligos experienced a net loss this quarter while maintaining cash reserves expected to support operations into late 2026. Additionally, the company continues to explore its pipeline developments, including ALG-055009 for metabolic conditions.
Read more →ALGSAligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025
Aligos Therapeutics, a clinical stage biotechnology company, has announced it will report its financial results for the second quarter of 2025 on August 6, 2025. The company is focused on developing therapies for liver and viral diseases, applying advanced R&D to address high unmet medical needs. The press release includes forward-looking statements that highlight risks and uncertainties associated with drug development and clinical trials, noting that actual results may differ significantly from expectations.
Read more →ALGSAntisense oligonucleotides as drugs with both direct and indirect antiviral actions
The article discusses the role of antisense oligonucleotides as antiviral agents, highlighting their potential for both direct and indirect actions against viruses. It also covers various aspects of the company's management, pipeline, and clinical trials related to chronic HBV infection. However, specific details on the efficacy or recent developments are not provided.
Read more →ALGSDiscovery and Preclinical Profile of ALG-097558, a Pan-Coronavirus 3CLpro Inhibitor
The article discusses the discovery and preclinical profile of ALG-097558, a pan-coronavirus 3CLpro inhibitor. It outlines the potential implications of this compound in treating coronavirus infections. However, specific details regarding efficacy or clinical trial results are not provided in the text.
Read more →ALGS▲ +11.2%on this news
Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)
Aligos Therapeutics has appointed Kieron Wesson, PhD, as Vice President and Head of Chemistry Manufacturing Controls (CMC). With over two decades of experience in the pharmaceutical industry, Wesson is expected to provide crucial leadership as Aligos progresses towards its Phase 2 study of ALG-000184, aimed at treating liver and viral diseases. His previous roles include significant contributions to drug development and successful product launches, enhancing Aligos's capabilities in meeting unmet medical needs.
Read more →ALGSAligos Therapeutics to Present at the Jefferies Global Healthcare Conference
Aligos Therapeutics, Inc. announced that its management will present at the Jefferies Global Healthcare Conference on June 5, 2025. The company specializes in developing therapies for liver and viral diseases, emphasizing its commitment to improve patient outcomes. A live webcast of the presentation will be available on their website, with a replay accessible for at least 30 days. Aligos is actively advancing its pipeline targeting conditions such as chronic hepatitis B and metabolic dysfunction-associated steatohepatitis.
Read more →ALGSEuropean Association for the Study of the Liver Congress (EASL) 2025 Satellite Symposium Recording
The article provides an overview of the European Association for the Study of the Liver (EASL) Congress 2025 Satellite Symposium. It includes sections on management, science pipeline, clinical trials, and investor relations. However, it lacks specific details about the symposium's content or outcomes.
Read more →ALGSAligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal
Aligos Therapeutics has appointed Laura Kavanaugh as Vice President and Head of Legal. Kavanaugh brings over 25 years of experience in the biotechnology and pharmaceutical industries, having previously worked at Codexis, Genentech, and Elan Pharmaceuticals. The Executive Vice President welcomed her, emphasizing the value of her extensive legal expertise for the company's mission focused on improving patient outcomes in liver and viral diseases. Kavanaugh expressed enthusiasm about joining the team and navigating the legal complexities to support the company's goals.
Read more →ALGS▲ +26.8%on this news
Population pharmacokinetic/pharmacodynamic modelling of novel thyroid hormone receptor beta agonist ALG-055009 reveals statistically significant correlation between exposure and key efficacy endpoints
The article discusses the population pharmacokinetic and pharmacodynamic modeling of ALG-055009, a novel thyroid hormone receptor beta agonist. The findings reveal a statistically significant correlation between drug exposure and key efficacy endpoints, indicating its potential effectiveness in treating chronic HBV infection. This research may pave the way for better therapeutic strategies.
Read more →ALGS▼ -8%on this newsshared move
ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic dysfunction-associated steatohepatitis, induces pro-metabolic and anti-fibrotic gene expression in the liver of diet-induced obese mice
The article discusses ALG-055009, a selective thyroid hormone receptor beta agonist, which has shown promising results in inducing pro-metabolic and anti-fibrotic gene expression in the liver of diet-induced obese mice. This suggests its potential for treating metabolic dysfunction-associated steatohepatitis. The findings highlight the drug's efficacy and its role in metabolic health.
Read more →ALGS▼ -8%on this newsshared move
Next generation hepatitis B virus antisense oligonucleotides incorporating novel chemistries demonstrated significantly improved properties compared to current clinical candidates
The article discusses the advancements in hepatitis B virus antisense oligonucleotides that incorporate novel chemistries. These new candidates have demonstrated significantly improved properties compared to existing clinical options. This development could lead to more effective treatments for chronic HBV infection.
Read more →ALGS▲ +11.7%on this news· ran to +36% by day 3shared move
ALG-055009, a novel thyroid hormone receptor beta agonist, demonstrated significant reductions in atherogenic lipids/lipoproteins, including lipoprotein (a), in patients with presumed metabolic dysfunction-associated steatohepatitis in the Phase 2a HERALD Study
The Phase 2a HERALD Study demonstrated that ALG-055009, a novel thyroid hormone receptor beta agonist, significantly reduced atherogenic lipids and lipoproteins, including lipoprotein (a), in patients with presumed metabolic dysfunction-associated steatohepatitis. This finding highlights the potential of ALG-055009 in addressing lipid-related issues in this patient population.
Read more →ALGS▲ +11.7%on this news· ran to +36% by day 3shared move
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025
Aligos Therapeutics announced positive results from eight presentations at the EASL Congress 2025, showcasing the potential of its therapies for liver and viral diseases. Notably, ALG-000184 achieved 100% HBV DNA suppression in chronic hepatitis B patients after 96 weeks of monotherapy. The presentation also highlighted the drug's best-in-class potential and robust antiviral activity, positioning it as a leading candidate for chronic HBV treatment. Additionally, ALG-055009 showed promising results in reducing liver fat content and improving atherogenic lipid profiles in metabolic disease patients.
Read more →ALGS▲ +11.7%on this news· ran to +36% by day 3shared move
ALG-055009, a novel thyroid hormone receptor beta (THR-beta) agonist, demonstrated robust reductions in liver fat at Week 12 across subgroups including glucagon-like peptide-1 (GLP-1) receptor agonist users in non-cirrhotic MASH patients in the Phase 2a HERALD study
The Phase 2a HERALD study of ALG-055009, a novel THR-beta agonist, showed significant reductions in liver fat at Week 12. This positive outcome was consistent across various subgroups, including patients using GLP-1 receptor agonists. The study specifically targeted non-cirrhotic MASH patients, highlighting its relevance in this population.
Read more →ALGS▲ +11.7%on this news· ran to +36% by day 3shared move
Viral kinetics and sequence analysis of a phase I monotherapy study in subjects with chronic hepatitis B reveals a high barrier of resistance to the capsid assembly modulator ALG-000184
The article discusses the results of a Phase I study evaluating ALG-000184, a capsid assembly modulator, in patients with chronic hepatitis B. The findings reveal a significant barrier to resistance, suggesting the drug's potential effectiveness. The study contributes valuable insights into the management of chronic HBV infection.
Read more →ALGS▲ +11.7%on this news· ran to +36% by day 3shared move
Monotherapy with the Novel Capsid Assembly Modulator ALG-000184 for up to 96 Weeks Results in Profound and Sustained HBV DNA Suppression in Untreated Subjects with Chronic HBV Infection
The article discusses the results of a study on ALG-000184, a novel capsid assembly modulator, which demonstrated profound and sustained suppression of HBV DNA in untreated subjects with chronic HBV infection over a treatment period of up to 96 weeks. This finding highlights the potential of ALG-000184 in managing chronic HBV infections effectively.
Read more →ALGS▲ +11.7%on this news· ran to +36% by day 3shared move
The Safety and Antiviral Effect of Oral Daily 300 mg ALG-000184 in Combination with Entecavir for up to 96 Weeks in Untreated HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection
The article discusses a clinical study examining the safety and antiviral effects of ALG-000184 in combination with Entecavir for treating untreated HBeAg-positive subjects with chronic Hepatitis B virus infection. The treatment is administered orally at a daily dose of 300 mg over a period of up to 96 weeks. This research aims to provide insights into effective management strategies for chronic HBV infection.
Read more →ALGS▼ -9.3%on this newsshared move
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
Aligos Therapeutics, Inc. reported strong business progress and financial results for Q1 2025. The company successfully raised over $100 million to advance its Phase 2 study of ALG-000184 for chronic hepatitis B, with promising data suggesting it could become a standard treatment. Furthermore, ALG-055009 demonstrated significant reductions in liver fat among MASH patients in Phase 2 trials. The company's financial health improved, reporting a net income of $43.1 million, signaling positive momentum in their developmental pipeline.
Read more →ALGSAligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
Aligos Therapeutics, Inc. has announced it will report its first quarter 2025 financial results on May 6, 2025, before the U.S. market opens. The company is focused on developing innovative therapies for liver and viral diseases, including chronic hepatitis B and metabolic dysfunction-associated steatohepatitis. Aligos is currently in a clinical stage and emphasizes a science-driven approach in its drug development pipeline. The press release also highlights various risks associated with forward-looking statements that could impact the company’s future performance.
Read more →ALGSAligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025
Aligos Therapeutics announced that eight abstracts have been accepted for poster presentations at the EASL Congress 2025 in Amsterdam. The research focuses on their promising therapies for chronic hepatitis B and metabolic dysfunction-associated steatohepatitis. Notable studies include their small molecule capsid assembly modulator ALG-000184 and the thyroid hormone receptor beta agonist ALG-055009. These presentations will feature significant findings on sustained HBV DNA suppression and reductions in liver fat in affected patients.
Read more →ALGS▼ -9.5%on this news· ran to -29% by day 3
ALG-055009, a Novel Thyroid Hormone Receptor Beta (THR-β) Agonist, was Well-tolerated with Significant Reductions in Liver Fat at Week 12 in Non-cirrhotic MASH Patients in the Randomized, Double-Blind, Placebo-controlled Phase 2a HERALD Study
The Phase 2a HERALD study demonstrated that ALG-055009, a novel THR-β agonist, was well-tolerated and resulted in significant reductions in liver fat after 12 weeks in non-cirrhotic MASH patients. This randomized, double-blind, placebo-controlled trial highlights the potential of ALG-055009 in treating liver fat accumulation.
Read more →ALGSMonotherapy with the Capsid Assembly Modulator ALG-000184 Results in High Viral Suppression Rates in Untreated HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection
The article discusses the promising results of monotherapy with the capsid assembly modulator ALG-000184, which has shown high viral suppression rates in untreated HBeAg-positive subjects with chronic Hepatitis B virus infection. This development suggests a potential new treatment avenue for managing chronic HBV infections. The study highlights the efficacy of ALG-000184, indicating its significance in the ongoing fight against Hepatitis B.
Read more →ALGS▼ -5.6%on this news· ran to -22% by day 3shared move
Monotherapy with the Capsid Assembly Modulator ALG-000184 Results in Rapid Viral Load Reduction and High Viral Suppression Rates in Untreated HBeAg-Negative Subjects with Chronic Hepatitis B Virus Infection
The study on ALG-000184, a capsid assembly modulator, demonstrated significant efficacy in reducing viral load and achieving high suppression rates in untreated HBeAg-negative patients with chronic hepatitis B virus infection. This monotherapy approach shows potential as a viable treatment option for this patient population.
Read more →ALGS▼ -10.1%on this news· ran to -23% by day 3shared move
Aligos Therapeutics Presents Positive Data at APASL 2025
Aligos Therapeutics announced promising data from its presentations at the APASL 2025 meeting. Their lead candidate, ALG-000184, demonstrated high rates of HBV suppression in both HBeAg-positive and negative patients, suggesting its potential as a first-line therapy. Additionally, ALG-055009 showed significant reductions in liver fat in MASH patients, with favorable tolerability. The results point to a strong clinical profile for both therapies, indicating potential advancements in treatment options for these diseases.
Read more →ALGS▼ -19.6%on this news
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
Aligos Therapeutics has reported significant business progress and financial results for 2024, outlining advancements in its clinical pipeline. The clinical-stage company is moving its lead candidate, ALG-000184, closer to a Phase 2 study, anticipated to commence in mid-2025. They also secured $105 million in financing, supporting their ongoing development of therapies for chronic hepatitis B and metabolic-associated steatotic liver disease (MASH). However, Aligos encountered a substantial net loss of $131.2 million for the year, highlighting some financial challenges amidst its progress.
Read more →ALGS▼ -14%on this news
Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025
Aligos Therapeutics, Inc. has announced that it will report its fourth quarter 2024 financial results on March 10, 2025, before U.S. markets open. The company is engaged in developing innovative therapies for liver and viral diseases, including chronic hepatitis B and metabolic dysfunction-associated steatohepatitis. This announcement follows a commitment to advancing their clinical-stage pipeline to meet unmet medical needs. The release also contains forward-looking statements about potential risks and uncertainties associated with drug development processes.
Read more →ALGS▼ -19.3%on this news
Aligos Therapeutics Announces $105 Million Private Placement Financing Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into the second half of 2026
Aligos Therapeutics has announced a $105 million private placement to fund the initial stages of its Phase 2 clinical study for ALG-000184, aimed at treating chronic hepatitis B. The financing, secured from a life sciences investment firm among other institutional investors, is anticipated to extend the company's operational cash runway into the latter half of 2026. The private placement involves the sale of several shares and warrants, set to close on February 13, 2025, subject to customary closing conditions.
Read more →ALGSAligos Therapeutics to Present at Investor Conferences in December
Aligos Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two investor conferences scheduled for December 3, 2024. The company will present at the Piper Sandler 36th Annual Healthcare Conference and the Evercore ISI 7th Annual HealthCONx Conference. Both presentations will be webcasted, and Aligos management will also conduct one-on-one meetings with investors. Aligos focuses on innovative therapies for liver and viral diseases, highlighting its commitment to improving patient outcomes.
Read more →ALGSThe Discovery and Preclinical Profile of ALG-000184, a Prodrug of the Potent Hepatitis B Virus Capsid Assembly Modulator ALG-001075
The article discusses the discovery and preclinical profile of ALG-000184, a prodrug related to the potent Hepatitis B virus capsid assembly modulator ALG-001075. It highlights the company's focus on chronic HBV infection and outlines its pipeline and clinical trials. However, specific details regarding the drug's efficacy or safety are not provided.
Read more →ALGS▼ -8.1%on this newsshared move
ALG-055009, a Novel Thyroid Hormone Receptor Beta (THR-β) Agonist, was Well-tolerated with Significant Reductions in Liver Fat at Week 12 in Non-cirrhotic MASH Patients in the Ongoing Randomized, Double-Blind, Placebo-controlled Phase 2
The ongoing Phase 2 trial of ALG-055009, a novel thyroid hormone receptor beta agonist, has demonstrated significant reductions in liver fat in non-cirrhotic MASH patients at the 12-week mark. The treatment has been reported to be well-tolerated, indicating a positive safety profile. These findings contribute to the potential of ALG-055009 in managing liver conditions.
Read more →ALGS▼ -8.1%on this newsshared move
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
Aligos Therapeutics presented positive findings at the Liver Meeting 2024, showcasing promising data on its drug candidates ALG-000184 and ALG-055009. ALG-000184 demonstrated high rates of virus suppression in chronic hepatitis B patients, while ALG-055009 showed significant reductions in liver fat for patients with metabolic dysfunction-associated steatohepatitis. Both treatments have shown good safety profiles with no viral resistance or gastrointestinal-related adverse effects reported. These results underscore Aligos' commitment to addressing unmet medical needs in liver and viral diseases.
Read more →ALGSNonclinical Toxicology Profile of ALG-055009, a Novel and Potent Thyroid Hormone Receptor β Agonist, for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
The article discusses the nonclinical toxicology profile of ALG-055009, a new thyroid hormone receptor beta agonist. This compound is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The findings suggest promising therapeutic potential for this condition.
Read more →ALGSCapsid Assembly Modulators Such as ALG-001075 Induce Profound HBV DNA Knockdown and Directly Target HBeAg In Vitro
The article discusses the promising effects of capsid assembly modulators, particularly ALG-001075, in inducing significant HBV DNA knockdown and directly targeting HBeAg in vitro. These findings suggest potential advancements in the treatment of chronic HBV infection. The research highlights the importance of continued exploration in this area.
Read more →ALGSMonotherapy with the Capsid Assembly Modulator, ALG-000184, Results in High Viral Suppression Rates in Untreated HBeAg+ and HBeAg- Subjects with Chronic Hepatitis B or Chronic Hepatitis B Virus Infection
The article discusses the promising results of ALG-000184, a capsid assembly modulator, showing high viral suppression rates in untreated patients with chronic Hepatitis B, both HBeAg+ and HBeAg-. This development highlights the potential of ALG-000184 in improving treatment outcomes for chronic HBV infection.
Read more →ALGSDiscovery and Preclinical Characterization of ALG-093940, a Potent and Orally Bioavailable Small Molecule PD-L1 Inhibitor for the Treatment of Cancer
The article discusses the discovery and preclinical characterization of ALG-093940, a new small molecule PD-L1 inhibitor. This compound is noted for its potent activity and oral bioavailability, which may enhance its application in cancer therapy. The findings suggest promising avenues for further development in clinical settings.
Read more →ALGSAligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
Aligos Therapeutics has reported business progress and third-quarter financial results, demonstrating significant advancements in clinical trials. Key achievements include positive data from the alg-055009 HERALD study for metabolic dysfunction-associated steatohepatitis (MASH) and ongoing development of ALG-000184 for chronic hepatitis B. The company continues to explore funding options including potential partnerships while facing financial challenges with a net loss reported at $19.3 million. Aligos projects more pivotal developments in 2025 following these promising results.
Read more →ALGSAligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
Aligos Therapeutics, Inc. will announce its financial results for the third quarter of 2024 on November 6, 2024. The company is engaged in developing therapies aimed at improving patient outcomes for liver and viral diseases, including hepatitis B. Their pipeline reflects a strong commitment to addressing high unmet medical needs. The announcement follows the standard practice of reporting financial results after market close to provide investors with relevant updates.
Read more →ALGSAligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
Aligos Therapeutics has received FDA clearance for its IND application related to ALG-000184, a drug aimed at treating Chronic Hepatitis B. This approval allows the company to proceed with a Phase 1 Drug-Drug Interaction study and set the stage for a Phase 2 trial filing anticipated in Q1 2025. The drug candidate is noteworthy as it is the first oral therapy designed to disrupt multiple stages of the HBV lifecycle, demonstrating strong antiviral capabilities in preliminary studies. Aligos affirms its commitment to developing innovative treatments for liver diseases.
Read more →ALGSAligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
Aligos Therapeutics, Inc. announced the acceptance of four abstracts for presentation at The Liver Meeting (TLM) 2024, including one late-breaker oral presentation. The data includes findings on ALG-000184, which demonstrates high viral suppression rates in chronic hepatitis B patients, and ALG-055009, which showed significant liver fat reduction in MASH subjects. These presentations will take place between November 15 and November 19, 2024, in San Diego, CA. This opportunity aligns with Aligos' mission to advance therapies for liver and viral diseases.
Read more →ALGSTwo Pre-clinical Short Interfering RNA (siRNA) Molecules Targeting Human HSD17β13 for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
The article discusses the development of two pre-clinical short interfering RNA (siRNA) molecules aimed at targeting human HSD17B13. These molecules are being investigated for their potential in treating metabolic dysfunction-associated steatohepatitis (MASH). This research represents a significant step forward in addressing metabolic diseases.
Read more →ALGSDiscovery and Optimization of the Pre-Clinical Efficacy of Human PNPLA3-Targeting Short Interfering RNA Molecules (siRNAs) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
The article discusses the discovery and optimization of short interfering RNA (siRNA) molecules targeting human PNPLA3 for treating metabolic dysfunction-associated steatohepatitis (MASH). It highlights the pre-clinical efficacy of these molecules. However, detailed results or implications are not provided in the text.
Read more →ALGSAligos Therapeutics Appoints David Perry as Vice President of Business Development
Aligos Therapeutics has appointed David Perry as Vice President of Business Development, effective immediately. With over 20 years of experience in the life sciences sector, Perry is expected to leverage his expertise to strengthen partnerships and advance Aligos's clinical pipeline. Notably, the company recently reported positive topline data for its candidate ALG-055009, marking a significant moment for the firm's growth and strategic direction.
Read more →ALGS▲ +7.7%on this newsshared move
Aligos Therapeutics to Present at Investor Conferences in October
Aligos Therapeutics, Inc. has announced that its management will participate in two investor conferences in October 2024. The events include the H.C. Wainwright 8th Annual MASH Virtual Conference and the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference. Both conferences will feature fireside chats and will be webcast live, with replays available for at least 30 days. Aligos is focused on developing therapies for liver and viral diseases, particularly for conditions with significant unmet needs.
Read more →ALGSAligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
Aligos Therapeutics has appointed Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will oversee the company's global clinical development efforts and is expected to contribute significantly due to his vast experience in hepatology and infectious diseases. The company is currently focused on advancing its pipeline of therapies for liver and viral diseases and is buoyed by recent positive data from clinical trials. Dr. Achneck’s experience includes previous leadership roles at other biopharmaceutical companies, positioning him as a key player in Aligos's strategic initiatives.
Read more →ALGS▼ -28.1%on this news· ran to -42% by day 3shared move
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
Aligos Therapeutics has announced positive topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta agonist aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). The study demonstrated significant reductions in liver fat, with up to 46.2% median relative reduction at Week 12. The treatment was well-tolerated, showing no serious adverse events and similar gastrointestinal issues compared to placebo. These encouraging results suggest further development of ALG-055009 is warranted, with plans for a Phase 2b study by mid-2025.
Read more →ALGSAligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
Aligos Therapeutics, Inc. is set to announce topline results from the Phase 2a HERALD study of its drug ALG-055009 for metabolic-dysfunction associated steatohepatitis (MASH) on September 19, 2024. Following the announcement, a conference call and webcast will take place to discuss the findings. The company emphasizes its mission to improve patient outcomes through innovative therapies for liver and viral diseases. Investors and stakeholders will be keenly awaiting the results to assess the drug's efficacy and implications.
Read more →ALGS▼ -5.6%on this news
Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone
The article provides an overview of ALG-055009, a selective thyroid hormone compound developed by Aligos Therapeutics. It discusses the company's management, pipeline, and various clinical trials related to chronic HBV infection. However, specific details about the discovery and preclinical profile of ALG-055009 are not included.
Read more →ALGS▲ +8.6%on this news
Kristina Engeseth, M.B.A.
Kristina Engeseth, M.B.A., joined Aligos in 2021 as Senior Vice President, Head of People & Culture. With over 20 years of HR experience, she has worked with notable companies including Nike and Google. Her career began in healthcare with Janssen Pharmaceutical, and she holds degrees from the University of Wisconsin-Madison.
Read more →ALGS▲ +9.4%on this newsshared move
Rámon Polo
Dr. Ramón Polo has joined Aligos as the Senior Vice President, Head of Global Regulatory Affairs. With a robust background in regulatory strategies across various therapeutic areas, including infectious diseases, he previously held significant roles at Shionogi and Johnson & Johnson. Dr. Polo's expertise is anticipated to strengthen Aligos' regulatory framework.
Read more →ALGSAligos Therapeutics Announces Reverse Stock Split
Aligos Therapeutics has announced a 1-for-25 reverse stock split of its common stock, effective August 19, 2024, to comply with Nasdaq's minimum bid price requirement. Shareholders will see their holdings adjusted accordingly and will be compensated for any fractional shares. The decision was approved by stockholders during the Annual Meeting and aims to stabilize the company's stock price amidst ongoing uncertainties in the drug development landscape. Instructions for shareholders regarding the split will be provided through their brokers.
Read more →ALGSBridget Martell
Bridget Martell, M.A., M.D., has been a board member since November 2021. She previously served as CEO of Artizan Biosciences and has held various leadership roles in multiple biopharmaceutical companies. Dr. Martell has a robust educational background, including a B.S. in microbiology and an M.D. from the Chicago Medical School.
Read more →ALGSJames Scopa
James Scopa has been a board member since April 2021, bringing significant experience from his previous roles at MPM Capital and Deutsche Banc Alex. Brown. He has advised numerous growth companies in biopharmaceuticals and medical devices and currently serves on the boards of several biotech firms. Scopa's educational credentials include an A.B., M.B.A., and J.D. from Harvard.
Read more →ALGSHeather Preston
Heather Preston is a seasoned healthcare investor with over 30 years of experience. Currently, she serves as a Senior Advisor to TPG Biotech and holds board positions at several biotech companies. Her previous roles include Managing Partner at Pivotal BioVentures and extensive experience in consulting and investing. Dr. Preston has a strong academic background in biochemistry and medicine.
Read more →ALGSCarole Nuechterlein
Carole Nuechterlein, J.D., has been a board member since August 2018 and previously led the Roche Venture Fund until her retirement in April 2026. She has overseen investments in several notable companies and served on various boards, showcasing her extensive experience in the biopharma sector. Nuechterlein also has a strong educational background with degrees from Valparaiso University and the University of Michigan.
Read more →ALGSK. Peter Hirth
K. Peter Hirth, Ph.D., has been on the board of directors since August 2018. He co-founded Plexxikon, Inc. and served as its CEO until 2013. Currently, he holds board positions at IO Biotech and Vaxcyte, among others. Dr. Hirth has a strong academic background with degrees from Heidelberg University and post-doctoral work at UC San Diego.
Read more →ALGSMargarita Chavez
Margarita Chavez is a highly experienced biopharmaceutical executive with over 25 years in the industry. Currently a Venture Partner at Wellington Partners, she also serves on the Board of Newron Pharmaceuticals. Her past roles include Managing Director at AbbVie Ventures, where she oversaw numerous investments in biotech companies. Additionally, she has a legal background in corporate and securities law.
Read more →ALGSTse-I Lin
Dr. Tse-I Lin is the Senior Vice President of Early Compound Development at Aligos Therapeutics in Belgium. He has a rich background in antiviral drug research, having worked at Bayer, JNJ, and Roche. His leadership roles have focused on HBV and HCV, significantly impacting drug development in these areas.
Read more →ALGSDavid B. Smith
David B. Smith, Ph.D., has been the Executive Vice President and Head of Chemical Operations at Aligos since August 2018. He oversees all Discovery Chemistry functions and is responsible for the company's Intellectual Property portfolio. With over 25 years in the field, he has contributed significantly to the development of drug candidates in liver and infectious diseases.
Read more →ALGSAligos Therapeutics Strengthens Board with Two New Independent Directors
Aligos Therapeutics has appointed Heather Preston, M.D. and Margarita Chavez, J.D. as independent directors to its board, effective August 7, 2024. Dr. Preston, who has over 30 years of experience in healthcare investment and company building, will chair the Nominating and Corporate Governance Committee. Ms. Chavez, who has more than 25 years of dealmaking experience in the healthcare industry, will join the Audit Committee. Both directors bring substantial expertise and expressed excitement about contributing to Aligos's growth and its promising drug candidates.
Read more →ALGSAligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
Aligos Therapeutics has reported significant progress in its clinical programs and financial results for the second quarter of 2024. The company successfully completed enrollment ahead of schedule for its Phase 2a HERALD study of ALG-055009, with topline data expected in early Q4 2024. Additionally, data presented at the EASL Congress 2024 showed encouraging results for ALG-000184, indicating strong antiviral activity in chronic hepatitis B patients. The FDA has provided positive feedback for subsequent studies, further bolstering Aligos’ portfolio of drug candidates.
Read more →ALGS▼ -5.2%on this newsshared move
Jim Hassard
James Hassard has been appointed as Executive Vice President and Chief Commercial Officer at Aligos. He previously held similar roles at Crinetics Pharmaceuticals and Arrowhead Pharmaceuticals, where he developed commercial strategies for rare disease programs. His career includes significant positions at Coherus Oncology, Amgen, and Merck, with a strong focus on launching pharmaceutical products across various therapeutic areas.
Read more →ALGS▼ -5.2%on this newsshared move
Sushmita M. Chanda
Sushmita M. Chanda, Ph.D., has been appointed as the Executive Vice President and Chief Development Officer at the company. She brings a wealth of experience from her previous roles at Alios BioPharma and F. Hoffman-La Roche. Dr. Chanda is a Diplomate of the American Board of Toxicology and has a solid educational foundation in Toxicology and Pharmacology.
Read more →ALGSLesley Ann Calhoun
Lesley Ann Calhoun has been the Executive Vice President and Chief Financial Officer of ALGS since June 2020. She has a robust background in finance, having held senior positions at multiple biopharmaceutical companies. Additionally, she serves as a Director at Tango Therapeutics and has a solid foundation in accounting from her early career at Deloitte.
Read more →ALGSJulian Symons
Julian A. Symons, D.Phil., has been the Executive Vice President and Chief Scientific Officer since May 2018. He previously worked at Alios BioPharma and held various roles at F. Hoffman-La Roche and several universities. His educational qualifications include a B.Sc. in Biochemistry and Physiology and a D.Phil. in Immunology.
Read more →ALGSLawrence M. Blatt
Lawrence M. Blatt, Ph.D., M.B.A., has been the CEO of ALGS since February 2018. He previously held significant roles at Janssen Pharmaceuticals and co-founded Alios BioPharma. Dr. Blatt's experience spans leadership positions in various biotech firms, and he holds degrees in Microbiology, Business Administration, and Public Health Administration.
Read more →ALGSSandra Chang
Sandra Chang highlights the positive aspects of working at Aligos, emphasizing the company's transparency and the strong connection employees feel towards its goals. She describes the culture as friendly and small, while noting that the team is focused on making a significant impact. The swift yet purposeful movement of the company is also mentioned.
Read more →ALGSDinah Misner
The article provides an overview of the company ALGS, detailing its management, board of directors, and various aspects of its operations including clinical trials and investor relations. It highlights the company's focus on chronic HBV infection and MASH, along with resources for investors. However, it lacks specific news or developments.
Read more →ALGSYannick Debing
Yannick Debing expresses enthusiasm about joining Aligos, highlighting the opportunity to lead a Discovery project. He appreciates the fast-paced work environment and the collaborative nature of the team, which has contributed to his professional growth as a scientist.
Read more →ALGSAligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024
Aligos Therapeutics, a clinical-stage biopharmaceutical firm, has announced it will report its second quarter 2024 financial results on August 6, 2024. The company focuses on developing therapeutics for liver and viral diseases, including hepatitis B and MASH. This announcement may reflect ongoing operational viability, but it also highlights the challenges and uncertainties typical of the drug development process. Risks mentioned include regulatory hurdles and reliance on third parties for manufacturing and development.
Read more →ALGS▲ +11.1%on this news
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
Aligos Therapeutics has announced a clinical trial collaboration with Xiamen Amoytop Biotech Co., Ltd. to evaluate the efficacy and safety of ALG-000184 alongside PEGBING® in chronic hepatitis B patients. The Phase 1b exploratory study will begin following approval from China’s National Medical Products Administration. This partnership aims to explore the potential benefits of a new treatment combination against chronic hepatitis B, leveraging the strengths of both therapeutics. Previous studies indicate that ALG-000184 has demonstrated strong antiviral activity and safety, paving the way for this collaboration.
Read more →ALGS▲ +7.9%on this news
Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
Aligos Therapeutics will host a KOL event on July 18, 2024, featuring Dr. Mark Sulkowski, to discuss the positive Phase 1b data for ALG-000184 regarding chronic hepatitis B (CHB). The event will highlight FDA feedback supporting the chronic suppression regulatory pathway and development plans. The data presented indicates ALG-000184's significant efficacy, with reductions in HBV DNA levels, and suggests a potential for superiority over existing treatments. Participants are required to register for the webinar to attend or view the replay later.
Read more →ALGSAligos Therapeutics Presents Positive Data at the EASL Congress 2024
Aligos Therapeutics presented promising data at the EASL Congress 2024, highlighting the efficacy of ALG-000184 in treating chronic hepatitis B (CHB). The results showcased sustained HBV DNA suppression in 90% of HBeAg-positive subjects and complete viral suppression in all HBeAg-negative subjects. Alongside these findings, the safety profile of ALG-000184 was noted to be favorable, with no viral breakthroughs reported across the studies. Additional presentations at the congress explored future siRNA treatments for metabolic diseases, enhancing Aligos' innovative portfolio.
Read more →ALGSDosing with the Capsid Assembly Modulator ALG-000184 in Untreated HBeAg Negative CHB Subjects Results in Potent Antiviral Effects Including Suppression of HBV DNA/RNA and Declines in HBcrAg Levels
The article discusses the promising results of dosing with the Capsid Assembly Modulator ALG-000184 in untreated HBeAg negative chronic hepatitis B (CHB) subjects. The treatment demonstrated potent antiviral effects, including significant suppression of HBV DNA and RNA levels, as well as declines in HBcrAg levels. These findings suggest a potential advancement in the management of chronic HBV infection.
Read more →ALGSExtended Treatment of HBeAg+ CHB Subjects with the Capsid Assembly Modulator ALG-000184 with or without Entecavir is Associated with Reductions in Viral Markers and Favorable Anti-HBeAg trends
The article discusses the positive outcomes of extended treatment with ALG-000184 in HBeAg+ chronic hepatitis B subjects. The treatment is associated with significant reductions in viral markers and favorable trends in anti-HBeAg. The results suggest a potential benefit of combining ALG-000184 with Entecavir.
Read more →ALGSAssociation of Baseline Characteristics and Plasma ALG-001075 to HBsAg Responses in HBeAg+ CHB subjects following ALG-000184±ETV treatment
The article discusses the association of baseline characteristics and plasma ALG-001075 levels with HBsAg responses in HBeAg+ chronic hepatitis B subjects after treatment with ALG-000184±ETV. It provides insights into the clinical trial aspects but lacks specific results or conclusions.
Read more →ALGSIn vitro and in vivo pharmacological characterization of human PNPLA3-targeting short interfering RNA molecules for the treatment of metabolic dysfunction-associated steatohepatitis
The article discusses the pharmacological characterization of human PNPLA3-targeting short interfering RNA molecules aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). It highlights the potential of these RNA molecules in addressing metabolic disorders. However, specific results or implications from the study are not detailed in the provided text.
Read more →ALGSNon-HAP CAM-A ALG-006746 and ALG-006780 induce rapid HBsAg reductions in AAV-HBV mice and have favorable pharmacokinetic profiles
The article discusses the promising results of CAM-A ALG-006746 and ALG-006780 in inducing rapid reductions of HBsAg in AAV-HBV mice. These compounds also demonstrate favorable pharmacokinetic profiles, suggesting potential for further development in treating chronic HBV infection. The findings may pave the way for future clinical trials.
Read more →ALGSSecond generation HBV siRNAs with novel chemistries demonstrate improved profiles compared with ALG-125755 and other clinical stage siRNAs
The article discusses the advancements in second generation HBV siRNAs, highlighting their improved profiles compared to ALG-125755 and other clinical stage siRNAs. These novel chemistries may offer enhanced efficacy in treating chronic HBV infections. The findings suggest a promising direction for future therapeutic developments in this area.
Read more →ALGSAligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
Aligos Therapeutics has announced that six of its research abstracts have been accepted for presentation at the EASL Congress 2024 in Milan, Italy, from June 5-8. Among these, two abstracts have been designated as 'Top' abstracts, reflecting their importance in the field of liver diseases. The presentations will cover various advancements in treatments for chronic hepatitis B and metabolic dysfunction-related liver conditions. This recognition highlights Aligos Therapeutics' commitment to addressing unmet medical needs in liver and viral diseases.
Read more →ALGSAligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
Aligos Therapeutics has announced the completion of enrollment in its Phase 2a HERALD study for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with ALG-055009. Topline safety and efficacy data are expected in early Q4 2024, led by Principal Investigator Dr. Rohit Loomba. The study has enrolled around 100 subjects and focuses on assessing the drug's effectiveness and safety among patients with liver conditions. ALG-055009 is a thyroid hormone receptor beta agonist that previously demonstrated a favorable safety profile in Phase 1 trials.
Read more →ALGSAligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
Aligos Therapeutics reported its business progress and financial results for the first quarter of 2024, highlighting advancements in its clinical trials and sufficient cash reserves. The company commenced dosing in its Phase 2a HERALD study for the THR-β agonist ALG-055009, with topline data expected by the end of 2024. Financial results showed a net loss of $34.9 million, which was larger than previous year's losses. Despite these losses, Aligos maintains confidence in their operational funding through 2025.
Read more →ALGSAligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
Aligos Therapeutics, Inc. has announced that it will report its financial results for the first quarter of 2024 on May 7, 2024, after U.S. market close. The company focuses on developing therapeutics for liver and viral diseases, intending to leverage its team's expertise to meet high unmet medical needs. While the announcement is timely, the company also acknowledges the inherent risks associated with drug development and market conditions.
Read more →ALGS▼ -6.2%on this newsshared move
Safety and pharmacokinetics of single and multiple ascending doses of ALG-097558, a pan-coronavirus protease inhibitor, in healthy volunteers
The article discusses the safety and pharmacokinetics of ALG-097558, a pan-coronavirus protease inhibitor, in healthy volunteers. It highlights the study's focus on single and multiple ascending doses. However, specific results or findings from the study are not detailed in the provided text.
Read more →ALGSAligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
Aligos Therapeutics presented positive results from the Phase 1 study of ALG-097558 during the ESCMID 2024 conference. The data indicated that the pan-coronavirus protease inhibitor was well tolerated in healthy volunteers and can be dosed without the need for ritonavir. This study highlights the drug's potential as an effective and convenient alternative to existing coronavirus treatments. Aligos plans to advance this candidate further, focusing on addressing both current and future pandemics.
Read more →ALGSAligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
Aligos Therapeutics has expressed deep condolences over the passing of Stephen A. Harrison, MD, a significant contributor to their ongoing Phase 2a HERALD study for metabolic dysfunction-associated steatohepatitis (MASH). Harrison's expertise was crucial in advancing the MASH field and the drug approval process. Aligos stated that the HERALD study continues to enroll and dose subjects, remaining on track for expected results in Q4 2024. The company aims to leverage its capabilities to address unmet needs in liver and viral diseases.
Read more →ALGSAligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
Aligos Therapeutics, Inc. has announced its participation in the Piper Sandler Spring Biopharma Symposium 2024, scheduled for April 16-17 in Boston, Massachusetts. The company is focused on developing novel therapeutics for liver and viral diseases, particularly for conditions like metabolic dysfunction-associated steatohepatitis and hepatitis B. Their strategic approach leverages extensive drug development expertise, aiming to address significant unmet medical needs in these areas.
Read more →ALGSAn in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients
The article discusses the development of an in vivo duck hepatitis B virus model that mirrors the treatment outcomes of nucleic acid polymer therapies in chronic hepatitis B patients. This model aims to enhance understanding of chronic HBV infection and improve treatment strategies. The research highlights the significance of this model in clinical trials and patient management.
Read more →ALGSAligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
Aligos Therapeutics has initiated dosing in the Phase 2a HERALD study of ALG-055009, targeting subjects with metabolic dysfunction-associated steatohepatitis (MASH). This trial will evaluate safety and efficacy across various doses and is expected to report topline data by Q4 2024. The study represents an important milestone for Aligos, indicating progress in developing therapies to meet the rising demand for MASH treatments.
Read more →ALGSALG-000184 Has Favorable Antiviral Effect & Safety in Untreated Asian/Non-Asian HBeAg-Negative CHB Subjects
The article discusses the positive results of ALG-000184, an antiviral treatment for untreated HBeAg-negative chronic hepatitis B (CHB) subjects. The study highlights its favorable antiviral effects and safety profile, demonstrating efficacy across both Asian and Non-Asian populations. These findings may contribute to improved treatment options for chronic HBV infection.
Read more →ALGSALG-000184 (100 mg) + ETV Leads to Stronger Antiviral Effects Compared to ETV Alone in HBeAg-Positive CHB
The article discusses the positive results of ALG-000184 combined with ETV, demonstrating stronger antiviral effects compared to ETV alone in patients with HBeAg-positive chronic hepatitis B (CHB). This combination therapy may offer a more effective treatment option for this patient population, highlighting its potential in clinical settings.
Read more →ALGSALG-000184 (300 mg) ± Entecavir Results in Substantial HBV Antigen Declines in Untreated HBeAg-Positive Subjects with CHB
The study on ALG-000184 (300 mg) ± Entecavir shows significant declines in HBV antigens in untreated HBeAg-positive subjects with chronic hepatitis B (CHB). This indicates a promising potential for the treatment of chronic HBV infection. The results may enhance management strategies for patients with this condition.
Read more →ALGSPharmacodynamics of Multiple Ascending Oral Doses of ALG-055009, a THR β Agonist, in Hyperlipidemic Subjects
The article discusses the pharmacodynamics of ALG-055009, a THR β agonist, in hyperlipidemic subjects. It provides an overview of the clinical trials and management related to this drug. However, specific results or findings from the trials are not detailed in the provided text.
Read more →ALGSAligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
Aligos Therapeutics, Inc. presented promising clinical data for its drugs ALG-055009 and ALG-000184 at the APASL 2024 conference. Data from ALG-055009 Phase 1 studies indicated favorable pharmacodynamic effects on lipids. Oral presentations of ALG-000184 showed significant antiviral activity, suggesting its potential role in hepatitis B treatment. The company remains optimistic about its development strategy targeting unmet medical needs in liver diseases.
Read more →ALGSAligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
Aligos Therapeutics has announced the start of the Phase 2a HERALD study to evaluate ALG-055009 for metabolic dysfunction-associated steatohepatitis (MASH). Screening has begun at various clinical sites, with the first dosing anticipated in Q2 2024. The study aims to assess safety and efficacy, with topline results expected by Q4 2024. ALG-055009 has shown promising pharmacologic properties, raising hopes for improved treatment options for patients with this condition.
Read more →ALGSAligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
Aligos Therapeutics reported its business progress and financial results for Q4 and the full year of 2023. The company closed a $92 million PIPE financing and completed pivotal Phase 2a studies for its drug ALG-055009. Aligos highlighted promising antiviral activity in its ALG-000184 program for chronic hepatitis B. Despite an increase in net losses and operational expenses, the company maintains a robust cash position to support its upcoming initiatives and studies in 2024.
Read more →ALGSAligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
Aligos Therapeutics, Inc. has announced it will release its fourth quarter 2023 financial results on March 12, 2024. As a clinical-stage biopharmaceutical company, Aligos aims to develop novel therapeutics to address significant needs in the treatment of liver and viral diseases. The company underscores its reliance on a seasoned team and extensive experience in these areas. However, the announcement also highlights several risks and uncertainties inherent in drug development and market conditions that may impact future performances.
Read more →ALGS▲ +21.3%on this news· ran to +32% by day 3
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
Aligos Therapeutics, a clinical stage biopharmaceutical company, announced its participation in the Leerink Partners Global Biopharma Conference 2024, which will take place in Miami from March 11-13, 2024. The company is focused on developing therapeutics for liver and viral diseases. This event offers an opportunity for one-on-one meetings with potential investors, reflecting Aligos' commitment to advancing its strategic goals in the biopharmaceutical field.
Read more →ALGSAligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
Aligos Therapeutics announced it will host a virtual Key Opinion Leader event on March 7, 2024, to discuss its Phase 2a HERALD study of ALG-055009 for metabolic dysfunction-associated steatohepatitis (MASH). The event will feature Dr. Stephen Harrison, who will address the unmet needs in MASH treatment and the clinical profile of ALG-055009. This initiative underscores Aligos's commitment to developing solutions for pressing health challenges in liver diseases.
Read more →ALGS▼ -6.2%on this news
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
Aligos Therapeutics has appointed Jordyn Tarazi as Vice President of Investor Relations and Corporate Communications, along with Nikhil Aneja as Vice President of Finance, effective immediately. The company expressed confidence that their experience will contribute significantly to its growth and progression towards delivering meaningful clinical data later in 2024. These appointments are strategic as Aligos aims to enhance its capabilities in developing novel therapeutics for liver and viral diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH).
Read more →ALGSHello Everyone, At Aligos, we regularly evaluate our rewards and compensation approach to ensure our employee compensation is competitive, to reward you for your work and to show you how valued you are for your work. We
Aligos has announced a voluntary option exchange program aimed at retaining talent amid challenging market conditions where many stock options are underwater. This initiative will allow eligible employees to exchange certain outstanding options for replacement options. While specifics are still being finalized, the company stresses its commitment to competitive compensation and employee recognition. An information session about the program is scheduled for January 30, 2024.
Read more →ALGSAligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
Aligos Therapeutics presented promising clinical data at Hep-DART 2023, highlighting its candidates ALG-000184 for HBV and ALG-055009 for NASH. The data for ALG-000184 indicated significant reductions in HBV markers, suggesting potential for chronic suppression and functional cure. ALG-055009 was characterized by a favorable safety profile and distinct pharmacokinetic properties compared to its competitors. These findings are vital as Aligos prepares for further studies to validate these outcomes.
Read more →ALGSSynthesis and evaluation of highly potent HBV capsid assembly modulators (CAMs)
The article discusses the synthesis and evaluation of HBV capsid assembly modulators (CAMs) by Aligos Therapeutics. It highlights the company's focus on addressing chronic HBV infection through innovative therapeutic approaches. However, specific details about the findings or implications of the research are not provided.
Read more →ALGSLong-term Dosing with ALG-000184 in HBeAg Positive Subjects Results in Unprecedented Multi-log Reductions in HBV Markers Including HBsAg
The article discusses the results of long-term dosing with ALG-000184 in subjects positive for HBeAg, highlighting unprecedented reductions in HBV markers, including HBsAg. These findings suggest a significant advancement in the treatment of chronic HBV infection, potentially improving patient outcomes. The results may pave the way for further research and development in this area.
Read more →ALGSClass-A Cams Induce Cell Death Through HBV Core Protein Aggregation And Potentially Activate The Innate Immune Response
The article discusses the potential of Class-A cams to induce cell death via HBV core protein aggregation. This mechanism may also activate the innate immune response, suggesting a promising avenue for therapeutic development in chronic HBV infections. The findings could pave the way for innovative treatments targeting HBV.
Read more →ALGSDiscovery of a Liver Targeted Oral PD-L1 Small Molecule Inhibitor for the Treatment of Chronic Hepatitis B and Liver Cancer
The article discusses the discovery of a liver-targeted oral PD-L1 small molecule inhibitor aimed at treating chronic hepatitis B and liver cancer. This innovative approach could enhance treatment options for patients suffering from these conditions. The development reflects ongoing advancements in targeted therapies within the biopharma sector.
Read more →ALGSNonclinical Efficacy, Pharmacokinetic/Pharmacodynamic (PK/PD), and Toxicology Profile of ALG-055009, a Novel and Potent Thyroid Hormone Receptor β Agonist, for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
The article discusses the nonclinical efficacy, pharmacokinetics, and toxicology profile of ALG-055009, a new thyroid hormone receptor beta agonist. This compound shows promise as a treatment for metabolic dysfunction-associated steatohepatitis (MASH). The findings highlight its potential benefits in managing this condition.
Read more →ALGSPreclinical Resistance Profile and Antiviral Activity of the Best-in-Class CAM-E ALG-001075, the Parent Compound of ALG-000184
The article discusses the preclinical resistance profile and antiviral activity of CAM-E ALG-001075, which serves as the parent compound for ALG-000184. It highlights the ongoing research and development efforts in addressing chronic HBV infection. However, specific results or findings from the studies are not detailed in the provided text.
Read more →ALGSSafety, Pharmacokinetics, And Pharmacodynamics Of Multiple Ascending Oral Doses Of ALG-055009, A Thyroid Hormone Receptor Beta Agonist, In Hyperlipidaemic Subjects And Relative Bioavailability/food Effect Of A Solid Formulation In Healthy Volunteers
The article discusses the safety, pharmacokinetics, and pharmacodynamics of multiple ascending oral doses of ALG-055009, a thyroid hormone receptor beta agonist, in hyperlipidaemic subjects. It also covers the relative bioavailability and food effect of a solid formulation in healthy volunteers. The study aims to provide insights into the drug's efficacy and safety profile.
Read more →ALGSProlonged (>24 Week) Dosing with the Oral CAM-E Compound ALG-000184 Results In Multi-log Reductions In Hepatitis B Surface Antigen, HBV DNA, And HBV RNA Levels In Untreated E Antigen Postive Subjects With Chronic Hepatitis B
The study reports that prolonged dosing of the oral CAM-E compound ALG-000184 leads to significant reductions in hepatitis B surface antigen, HBV DNA, and HBV RNA levels in untreated E antigen positive subjects with chronic hepatitis B. These findings suggest the compound's potential effectiveness in managing chronic HBV infection.
Read more →ALGSAligos Therapeutics To Present at the Piper Sandler Healthcare Conference
Aligos Therapeutics, a clinical stage biopharmaceutical company, has announced its participation in the 2023 Piper Sandler Healthcare Conference. Lawrence M. Blatt, Ph.D., MBA, the CEO, will present on November 30, 2023, at 12:30 p.m. ET. The management team will also engage in one-on-one meetings with investors during the event. Aligos aims to lead in developing therapies for liver and viral diseases, targeting conditions with significant unmet medical needs.
Read more →ALGS▼ -14.1%on this news
Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models
The article discusses the efficacy of the STING agonist ALG-031048 in inducing tumor regression in mouse models. The results highlight the effectiveness of both intratumoral and subcutaneous dosing methods. These findings suggest a potential advancement in cancer treatment options, warranting further investigation into the therapeutic applications of ALG-031048.
Read more →ALGS▼ -14.1%on this newsshared move
Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile
Aligos Therapeutics presented promising clinical and nonclinical data for its drug ALG-055009 at the AASLD Liver Meeting 2023. The drug showed favorable tolerability and pharmacokinetics in a Phase 1 study, with significant reductions in lipid levels. Given its strong risk-benefit profile, a Phase 2a study is planned for patients with nonalcoholic steatohepatitis (NASH), set to start in Q1 2024. The company is optimistic about future developments and aims to address unmet medical needs in liver diseases.
Read more →ALGS▼ -10%on this news· ran to -23% by day 1shared move
LONG-TERM DOSING WITH THE CAPSID ASSEMBLY MODULATOR ALG-000184 RESULTS IN MULTI-LOG REDUCTIONS OF DNA, RNA, HBsAg, HBeAg AND HBcrAg IN UNTREATED HBeAg POSITIVE CHRONIC HEPATITIS B SUBJECTS
The article discusses the positive results from long-term dosing of the capsid assembly modulator ALG-000184, which led to multi-log reductions in DNA, RNA, HBsAg, HBeAg, and HBcrAg in untreated HBeAg positive chronic hepatitis B patients. These findings suggest a promising therapeutic approach for managing chronic HBV infection.
Read more →ALGS▼ -9.3%on this news· ran to -22% by day 1shared move
Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
Aligos Therapeutics showcased promising data for its ALG-000184 drug at the AASLD Liver Meeting 2023. The trial results indicate significant reductions in HBV antigens among HBeAg+ subjects treated with ALG-000184 and entecavir for up to 48 weeks. The treatments resulted in a favorable safety profile and no viral breakthroughs were observed with Alg-000184 monotherapy. The findings suggest ALG-000184 may play an important role in future hepatitis B therapies.
Read more →ALGSDiscovery of ALG-093989, a Highly Potent and Orally Bioavailable Small Molecule PD-L1 Inhibitor for the Treatment of Cancers
The article discusses the discovery of ALG-093989, a new small molecule PD-L1 inhibitor. This compound shows high potency and is designed to be orally bioavailable, which could improve treatment adherence among cancer patients. The development represents a significant advancement in cancer therapy options.
Read more →ALGSDiscovery of ALG-094103, a Liver-Targeted and Orally Bioavailable Small Molecule PD-L1 Inhibitor for the Treatment of Liver Cancer
The article discusses the discovery of ALG-094103, a novel small molecule PD-L1 inhibitor specifically designed for liver cancer treatment. This compound is notable for its liver-targeted approach and oral bioavailability, which may improve patient compliance and therapeutic outcomes. The development reflects ongoing efforts to address significant gaps in liver cancer therapies.
Read more →ALGSAligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data
Aligos Therapeutics announced it will host a virtual KOL event on November 16, 2023, to discuss the Late Breaking results of its Phase 1 clinical trial for ALG-000184, a drug candidate for chronic Hepatitis B. The event will be led by Dr. Mark Sulkowski from Johns Hopkins University, who will explore the current treatment landscape and unmet needs for patients. The Phase 1 data will also be presented at the AASLD Liver Meeting on November 13, 2023, in a late-breaking poster session.
Read more →ALGSAligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
Aligos Therapeutics has reported significant business progress and financial results for Q3 2023, including a successful private placement that raised $92 million and regulatory clearance for its drug ALG-055009's IND. The company is advancing multiple clinical programs, including a COVID-19 protease inhibitor and treatments for liver diseases. Despite the positive financial milestones, the company reported a net loss of $18 million for the quarter, although this reflects a minor improvement from the previous year. Aligos anticipates that its cash reserves will support operations through the end of 2025.
Read more →ALGSAligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023
Aligos Therapeutics, Inc. has announced that it will report its third quarterly financial results on November 2, 2023, after market close. The company, which focuses on developing novel therapies for liver and viral diseases, aims to lead in its field with innovative treatments. However, it acknowledges various risks associated with drug development, regulatory processes, and reliance on partners, as described in its forward-looking statements.
Read more →ALGSAligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting 2023
Aligos Therapeutics, Inc. announced the acceptance of an abstract detailing its CAM-E drug candidate, ALG-000184, as a late breaking poster at The Liver Meeting 2023. The study highlights long-term dosing results in significant reductions of important hepatitis B markers. The poster will be presented by Dr. Man-Fung Yuen from the University of Hong Kong on November 13, 2023. This presentation underscores Aligos's commitment to addressing unmet medical needs in liver diseases.
Read more →ALGS▼ -21.5%on this newsshared move
Aligos Therapeutics Announces $92 Million Private Placement Financing
Aligos Therapeutics announced a successful $92 million private placement financing aimed at advancing its drug development programs. The funds will primarily support the company's Phase 2a study for NASH, as well as activities related to its hepatitis B therapeutic candidate. With this financing, Aligos anticipates sufficient resources to maintain operations through the end of 2025. The placement is backed by institutional investment firms and is expected to close on October 25, 2023.
Read more →ALGSClass A capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation
The article discusses RG7907, a Class A capsid assembly modulator, which has demonstrated efficacy in clearing HBV-infected hepatocytes. The treatment operates through a mechanism that involves core-dependent hepatocyte death and subsequent proliferation. This development may open new pathways for treating chronic HBV infections.
Read more →ALGSAligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558
Aligos Therapeutics has been awarded an $8.5 million contract by the National Institute of Allergy and Infectious Diseases (NIAID) to support the development of their pan-coronavirus protease inhibitor, ALG-097558. This funding is intended to facilitate further nonclinical and clinical studies, advancing the program into future Phase 2/3 studies. ALG-097558 is currently undergoing a Phase 1 trial in healthy volunteers, with the potential to be important for managing current and future coronavirus infections. This contract marks the second instance of NIH funding to support the development of this candidate.
Read more →ALGSNovel non-HAP class A HBV capsid assembly modulators have distinct <em>in vitro</em> and <em>in vivo</em> profiles
The article discusses the profiles of novel non-HAP class A HBV capsid assembly modulators, highlighting their distinct in vitro and in vivo characteristics. It provides an overview of the management, pipeline, and clinical trials associated with chronic HBV infection. The content is primarily focused on the company's structure and investor-related information.
Read more →ALGSAligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
Aligos Therapeutics has announced FDA clearance of its Investigational New Drug application for ALG-055009, a thyroid hormone receptor beta agonist aimed at treating nonalcoholic steatohepatitis (NASH). The company plans to submit the Phase 2a study protocol by Q4 2023 and start patient enrollment in Q1 2024, with initial proof of concept data expected by Q4 2024. The upcoming study will assess the safety and efficacy of multiple dose levels against a placebo over a 12-week treatment period.
Read more →ALGSEstablishment of a robust rat hepatitis E virus fecal-oral infection model and validation for antiviral studies
The article discusses the establishment of a rat model for studying hepatitis E virus through fecal-oral infection. This model aims to enhance antiviral research efforts. The details regarding the methodology and potential applications of this model are highlighted, although specific results or findings are not provided.
Read more →ALGSAligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
Aligos Therapeutics reported its business progress and financial results for Q2 2023, highlighting advancements in several drug candidates targeting liver and viral diseases. The company is on track to file the Phase 2a protocol for its lead NASH program, ALG-055009, by Q4 2023. Meanwhile, clinical trials for COVID-19 protease inhibitor ALG-097558 are underway, with initial dosing completed. Financially, Aligos experienced a decrease in cash reserves and a slight increase in net losses compared to the previous year.
Read more →ALGSAligos Therapeutics to Announce Second Quarter Results on August 03, 2023
Aligos Therapeutics, a clinical stage biopharmaceutical company, has announced that it will release its second quarter 2023 financial results on August 03, 2023. The company is dedicated to developing novel therapeutics for liver diseases and viral infections, including NASH and chronic hepatitis B. Aligos emphasizes its experienced team and strategic approach to drug development. However, as a clinical-stage company, it faces inherent risks in the drug development process which may affect its future results.
Read more →ALGSAligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009
Aligos Therapeutics has announced the appointment of Dr. Stephen Harrison as the Principal Investigator for its Phase 2a study of the NASH drug candidate, ALG-055009. The Phase 1 study has been completed successfully, showing favorable results in terms of safety and pharmacokinetics. The upcoming Phase 2a trial will evaluate the drug's safety, pharmacokinetics, and efficacy over a 12-week period. Aligos is on track to file the IND for the Phase 2a study in Q4 2023, with topline results expected in Q4 2024.
Read more →ALGSAligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
Aligos Therapeutics presented data from its liver disease programs at the EASL Congress 2023, highlighting significant advancements in their drug candidates for chronic hepatitis B. Notable findings include the Phase 1b study results of ALG-000184 showing substantial reductions in HBsAg, DNA, and RNA levels. The company's presentations underscore their commitment to developing innovative treatments for liver diseases and improving patient outcomes. CEO Lawrence Blatt expressed optimism about their ongoing projects and plans for further data releases later this year.
Read more →ALGSAligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
Aligos Therapeutics will present data on its liver disease programs at the EASL Congress 2023 in Vienna, highlighting progress on multiple novel therapeutics. The company will showcase seven posters detailing results from clinical studies, including the promising effects of compounds like ALG-000184 and ALG-125755 on hepatitis B. CEO Lawrence Blatt emphasized the potential of these compounds representing best-in-class strategies in addressing unmet medical needs. Aligos aims to become a leader in treating liver diseases, reinforcing its commitment through these presentations at the prestigious congress.
Read more →ALGSAligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
Aligos Therapeutics, a clinical stage biopharmaceutical company, announced its participation in the Jefferies Healthcare Conference on June 8, 2023. CEO Lawrence Blatt will present, highlighting the company's commitment to addressing unmet medical needs in liver diseases and viral infections. The conference offers a platform for potential investors through one-on-one meetings. The event emphasizes Aligos's strategic focus on developing novel therapeutics for conditions like nonalcoholic steatohepatitis and chronic hepatitis B.
Read more →ALGSAligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos’ Oligonucleotide Platform for the Treatment of Liver Diseases
Aligos Therapeutics has formed a research collaboration and development agreement with Xiamen Amoytop Biotech Co. Ltd. aimed at using Aligos’ oligonucleotide platform for liver disease treatment in Greater China. The partnership allows Amoytop to license the resultant products while Aligos retains global rights. Aligos will receive an upfront payment and could earn up to $109 million in milestone payments, plus royalties on sales. Both companies express optimism about the potential impact of their collaboration in addressing liver diseases.
Read more →ALGSAligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
Aligos Therapeutics has reported a strong start to 2023, achieving key milestones in their clinical programs for liver and viral diseases. Significant progress has been made in their chronic hepatitis B and COVID-19 protease inhibitor programs, with upcoming IND filings anticipated for the NASH program. Financial results show a reduction in research and development expenses compared to the previous year, although the company continues to face net losses. The firm remains optimistic about funding operations through 2024 with a cash balance of $103.5 million.
Read more →ALGSAligos Therapeutics to Announce First Quarter Results on May 4, 2023
Aligos Therapeutics, Inc. announced that it will disclose its first quarter 2023 financial results on May 4, 2023. The company, focused on developing therapies for liver diseases and viral infections, positions itself as a leader in addressing unmet medical needs in these areas. The announcement emphasizes their commitment to transparency and highlights the potential risks involved in drug development, including the challenges of clinical trials and regulatory processes.
Read more →ALGSAligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023
Aligos Therapeutics, a clinical-stage biopharmaceutical company, will present data from five liver disease programs at the EASL Congress 2023 in Vienna. The presentations will highlight seven abstracts that aim to address chronic hepatitis B and hepatocellular carcinoma. Aligos believes their compounds have the potential to be best-in-class therapeutics, promising value for both patients and shareholders. Detailed results from the studies will be shared at the congress and throughout the year.
Read more →ALGSAligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference
Aligos Therapeutics recently presented Phase 1 clinical data for its THR-β agonist candidate, ALG-055009, at the 2023 Paris Hepatology Conference. The data indicated that the drug exhibited a favorable safety profile and pharmacokinetic parameters in healthy volunteers as well as subjects with hyperlipidemia. With the upcoming Phase 2 study on track for a regulatory filing in Q4 2023, the gelcap formulation showed low variability and comparable bioavailability to its liquid counterpart. However, the company noted that forward-looking statements involve inherent risks and uncertainties that could impact future developments.
Read more →ALGS▼ -6.2%on this news
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
Aligos Therapeutics has reported substantial progress in its clinical programs and financial results for 2022. The company is advancing its drug candidates for NASH, COVID-19, and chronic hepatitis B with promising clinical data. Notably, ALG-055009 has shown encouraging results that set it apart from other treatments in development. Aligos plans to submit a Phase 2 clinical trial application by the end of 2023, signaling confidence in their pipeline. Financially, the company reported reduced net losses and expects its available cash to fund operations through the end of 2024.
Read more →ALGS▼ -7%on this news
Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023
Aligos Therapeutics, Inc. has announced it will release its fourth quarter 2022 financial results on March 9, 2023. The company, based in South San Francisco, is dedicated to creating novel therapeutics for unmet medical needs in nonalcoholic steatohepatitis (NASH) and viral diseases. Aligos was founded in 2018 and aims to leverage its expertise in these fields to develop best-in-class molecules. Investors should watch for the upcoming financial results for insights into the company's performance.
Read more →ALGSAligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
Aligos Therapeutics presented updates at the APASL conference, highlighting promising data for their compounds targeting NASH and chronic hepatitis B. The thyroid hormone receptor-beta agonist, ALG-055009, exhibited beneficial anti-lipid effects in hyperlipidemia patients. Additionally, the capsid assembly modulator ALG-000184 demonstrated superior antiviral activity in HBeAg-positive chronic hepatitis B patients. These developments underscore Aligos' mission to provide innovative treatments for liver diseases.
Read more →ALGS▲ +7.2%on this newsshared move
Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
Aligos Therapeutics, a clinical-stage biopharmaceutical company, announced it will present multiple program updates at the 32nd APASL conference in Taipei, Taiwan. The presentations will include data on ALG-055009, a THR-β agonist aimed at treating nonalcoholic steatohepatitis (NASH), and findings from its chronic hepatitis B portfolio. The company aims to file for Phase 2 trials by the end of the year, demonstrating its commitment to addressing unmet medical needs in liver diseases.
Read more →ALGS▼ -11.1%on this newsshared move
Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference
Aligos Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Lawrence M. Blatt, will present at the SVB Securities Global Biopharma Conference on February 15, 2023. The company's focus is on developing therapeutics for liver diseases and viral infections, including NASH and targeted antiviral therapies. Aligos aims to leverage their expertise to advance their pipeline of potential therapies, though they acknowledge inherent risks in the drug development process. A replay of the presentation will be available for 90 days on their investor website following the conference.
Read more →ALGSAligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024
Aligos Therapeutics has announced a strategic reprioritization of its clinical pipeline, focusing on its NASH (ALG-055009) and COVID-19 (ALG-097558) programs. Alongside this realignment, the company will implement a workforce reduction of 25% since early 2022 to streamline operations and enhance its cash runway, which is projected to extend to the end of 2024. The firm has affirmed its commitment to advancing key drug candidates while continuing collaborations, particularly with Merck & Co.
Read more →ALGSAligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported today that dosing with
Read more →ALGSAligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting
Coronavirus protease inhibitor, ALG-097558, has demonstrated antiviral activity in vivo and promising pan-coronavirus activity in vitro First-in-human studies anticipated to begin in H1 2023 SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc
Read more →ALGS▼ -5.7%on this news
Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver Meeting 2022
ALG-055009, a THR-β agonist drug candidate in development as a treatment for NASH, demonstrated dose-dependent reductions in several atherogenic lipids and a favorable pharmacokinetic profile in subjects with hyperlipidemia Aligos’ oral and poster presentations also collectively
Read more →ALGSAligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business
Read more →ALGSAligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting 2022
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced seven upcoming
Read more →ALGSAligos Therapeutics to Announce Third Quarter Results November 2, 2022
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced
Read more →ALGSAligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced
Read more →ALGSAligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755
Single ascending doses to be evaluated in healthy volunteers in Q4 2022 Single ascending doses to be evaluated in subjects with chronic hepatitis B beginning in Q1 2023 SOUTH SAN FRANCISCO, Calif., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a cl
Read more →ALGSAligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, has filed a response to the co
Read more →ALGSAligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business
Read more →ALGSAligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022
SOUTH SAN FRANCISCO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will re
Read more →ALGSAligos Therapeutics Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating Its Class II Capsid Assembly Modulator, ALG-000184
SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported that enrollment
Read more →ALGSAligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for CAM Drug Candidate ALG-000184, First Clinical Data for NASH Drug Candidate ALG-055009 and Nonclinical Data in Other Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital International Liver Congress™ 2022
-Similar significant reductions of hepatitis B virus (HBV) DNA and HBV RNA observed following 28 days of daily oral ALG-000184 dosing, regardless of HBeAg status, across first four dosing chronic hepatitis B (CHB) patient cohorts -In the first clinical data presentation from our
Read more →ALGS▲ +9.2%on this news· ran to +22% by day 1
Aligos Therapeutics to Participate in Metropolitan AntiViral Drug Accelerator, Recipient of NIH and NIAID Grant to Develop Therapeutics Against Coronaviruses and Pathogens of Pandemic Potential
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the compan
Read more →ALGS▲ +8.3%on this news
Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M.
Read more →ALGSAligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business p
Read more →ALGSAligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s International Liver Congress™ 2022
SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company
Read more →ALGSAligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022
SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will r
Read more →ALGSAligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development
SOUTH SAN FRANCISCO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has se
Read more →ALGSAligos Discontinues Development of its Antisense Oligonucleotide Drug Candidate ALG-020572 in Subjects with Chronic Hepatitis B and Pivots Internal Strategic Emphasis to its Small Molecule Portfolio
Dosing in the first cohort discontinued after multiple reports of ALT flares suggestive of drug-induced liver toxicity Funds will be redirected to support ongoing clinical programs, including ALG-000184 (Class-II CAM for CHB) and ALG-055009 (THR- agonist for NASH), and to accele
Read more →ALGSAligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1b ASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1st cohort fully enrolled siRNA (ALG-125755) progressing on track through Phase 1 enabling nonclinical studies TH
Read more →ALGSAligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022
SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will r
Read more →ALGSAligos Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M
Read more →ALGSAligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)
Administration of single ascending doses up to 480 mg in healthy volunteers nearly complete First chronic hepatitis B patient dosed in initial cohort, each of which will be administered 7 subcutaneous doses over 29 days SOUTH SAN FRANCISCO, Calif., Jan. 26, 2022 (GLOBE NEWSWIRE
Read more →ALGS▲ +6.4%on this news
Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has expa
Read more →ALGSAligos Halting Further Development of STOPS™ Drug Candidate, ALG-010133
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has hal
Read more →ALGSAligos Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M
Read more →ALGSAligos Therapeutics Begins Dosing with NASH Drug Candidate, ALG-055009, in Healthy Volunteers in a Phase 1 First-in-Human Study
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the compan
Read more →ALGSAligos Presents Update of Chronic Hepatitis B Pipeline Portfolio at HEP DART 2021
New data from HBeAg-positive patients receiving 100 mg of ALG-000184 demonstrates similar PK and potent antiviral activity to previously reported data for HBeAg-negative patients New preclinical data with a novel oral small molecule PD-1/PD-L1 antagonist shows potential to induc
Read more →ALGSAligos Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M
Read more →ALGSAligos Therapeutics Appoints Bridget Martell, MA, M.D., to its Board of Directors
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the compan
Read more →ALGSAligos Therapeutics to Present Virtually at the Jefferies London Healthcare Conference 2021
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M
Read more →ALGSAligos Therapeutics Presents Data for its Chronic Hepatitis B (CHB) and Nonalcoholic Steatohepatitis (NASH) Portfolio at The Liver Meeting 2021
Several clinical and nonclinical posters to be presented at the conference Aligos’ capsid assembly modulator (CAM) candidate, ALG-000184, achieved rapid, substantial reductions in hepatitis B virus DNA and RNA in CHB patients after 28 daily doses SOUTH SAN FRANCISCO, Calif., No
Read more →ALGSAligos Therapeutics Reports Recent Business Progress and Third Quarter 2021 Financial Results
Dosing of ALG-020572 (ASO) in healthy volunteers underway Enrollment in first 2 STOPS cohorts (120, 200 mg) complete; enrollment in 3rd cohort (400 mg) underway Clinical trial application (CTA) filed for 1st NASH drug candidate, ALG-055009, a THR-beta agonist SOUTH SAN FRANCIS
Read more →ALGSAligos Therapeutics to Announce Third Quarter 2021 Results November 4, 2021
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will re
Read more →ALGSAligos Therapeutics to Present Data for its Clinical Portfolio Targeting Chronic Hepatitis B and NASH at AASLD’S The Liver Meeting 2021
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced upcoming poster
Read more →ALGSAligos Therapeutics Begins Dosing with Antisense Oligonucleotide Drug Candidate, ALG-020572, in Healthy Volunteers in a Phase 1 Proof-of-Concept Study
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the compan
Read more →ALGSAligos Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence
Read more →ALGSAligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results
Raised $83.6 million in gross proceeds from common stock offering STOPS™ and CAM programs: initial data presented at conferences, dosing in 2nd CHB cohorts ongoing Clinical trial application filed for 3rd CHB drug candidate ALG-0202572 (antisense oligonucleotide) – dosing in HV
Read more →ALGSAligos Therapeutics to Announce Second Quarter 2021 Results August 5, 2021
SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will re
Read more →ALGSAligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its underwritten public offering of 4,400,000 shares of common stock at a public offering price of $19.00 per share. In addition, Aligos has gran
Read more →ALGSAligos Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common stock. In addition, Aligos intends to grant the underwriters a 30-day option
Read more →ALGSAligos Therapeutics to Present Phase 1 Safety and Pharmacokinetic Data for STOPS™ Molecule Drug Candidate ALG-010133 and Several Nonclinical Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital International Liver Congress 2021
-First clinical data presented for ALG-010133, which is in development for S-antigen reduction in chronic hepatitis B (CHB) patients -Presentations include nonclinical data from 3 other CHB programs SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeut
Read more →ALGSAligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver’s Digital International Liver Congress 2021
-Five scientific posters to be presented at upcoming EASL ILC meeting - All 4 Aligos CHB development candidates continue to advance – STOPS™ molecule and CAM drug candidates are currently being evaluated in CHB subjects - ASO and siRNA drug candidates are on track to enter clini
Read more →ALGSAligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects at HBV-TAG Conference
Subjects experienced a 2.9 log10 IU/mL mean reduction in HBV DNA levels after 14 days’ dosing with 100 mg ALG-000184 Half (4 out of 8) of these subjects had HBV DNA levels below the lower limit of quantitation (LLOQ) on Day 14 SOUTH SAN FRANCISCO, Calif., June 10, 2021 (GLOBE N
Read more →ALGSAligos Therapeutics to Present at the Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence Bl
Read more →ALGSAligos Therapeutics Reports Recent Business Progress and First Quarter 2021 Financial Results
SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business p
Read more →ALGSAligos Therapeutics to Announce First Quarter 2021 Results May 10, 2021
SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will rep
Read more →ALGSAligos Therapeutics Appoints James Scopa, J.D., MBA, to its Board of Directors
SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the compa
Read more →ALGSAligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study
SOUTH SAN FRANCISCO, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the compa
Read more →ALGSAligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
- Advanced ALG-010133 and ALG-000184 into the clinic - both expected to generate safety and antiviral activity data in Chronic Hepatitis B (CHB) patients in 2021 - Listed on NASDAQ Global Select Market under the symbol ALGS and raised $167.2 million in gross proceeds from the In
Read more →ALGSAligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study
SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the compa
Read more →ALGSAligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic Infections
SOUTH SAN FRANCISCO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the compa
Read more →ALGSAligos Therapeutics Presents Data for its Chronic Hepatitis B Drug Candidates at the 30th Annual Conference of the Asian Pacific Association for the Study of the Liver
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the compan
Read more →ALGSAligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that CEO Lawren
Read more →ALGSAligos Therapeutics Presents Update on Development of SARS-CoV-2 Therapeutic Candidate and Screening Method in Collaboration with KU Leuven at RespiDART & Emerging Viruses 2020
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the compan
Read more →ALGSAligos Enters into an Exclusive License and Research Collaboration Agreement with Merck to Discover and Develop an Oligonucleotide Therapy for NASH
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has entered into an Exclusive License and Research Collaboration Agreement with Merck, known as MSD outside the United States and Canada, under which Me
Read more →ALGSAligos Therapeutics Presents Data on Chronic Hepatitis B, NASH and Hepatocellular Carcinoma Programs at AASLD’s The Liver Meeting Digital Experience™ 2020
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the compan
Read more →ALGSAligos Therapeutics Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that management
Read more →ALGSAligos Therapeutics is awarded €1.8M VLAIO grant to advance chronic hepatitis B research
SOUTH SAN FRANCISCO, Calif. and LEUVEN, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today annou
Read more →ALGSAligos Therapeutics Doses First Subject in Phase 1 Proof-of-Concept Study of Small Molecule Drug Candidate ALG-000184 for Chronic Hepatitis B
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has dos
Read more →ALGSAligos Therapeutics Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its initial public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share. In addition, Aligos has gran
Read more →ALGSAligos Therapeutics Presents Coronavirus Therapeutic Screening Assay Development at ISIRV-AVG Conference
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company is p
Read more →ALGSAligos Therapeutics Receives Clinical Trial Application Approval for Chronic Hepatitis B Capsid Assembly Modulator Candidate ALG-000184
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the Company has
Read more →ALGSAligos Therapeutics to Present Nonclinical Data for All Components of Chronic Hepatitis B Combination Therapy at EASL Digital International Liver Congress 2020
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a private biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B (CHB), COVID
Read more →ALGSAligos Therapeutics to Present Nonclinical NASH Update at EASL Digital International Liver Congress 2020
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a private biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B (CHB), COVID-1
Read more →ALGSAligos Therapeutics Submits Clinical Trial Application for Chronic Hepatitis B Capsid Assembly Modulator Candidate ALG-000184
SOUTH SAN FRANCISCO, Calif., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has submitted
Read more →ALGSAligos Therapeutics Doses First Subject in Phase 1 Proof of Concept Study of Oligonucleotide Drug Candidate ALG-010133
First Aligos drug candidate to commence clinical trials First-in-human trial marks ~2.5-year path from company formation to entry into the clinic SOUTH SAN FRANCISCO, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a private clinical stage biopharm
Read more →ALGSAligos Therapeutics and KU Leuven Announce Collaboration for the Development of a Therapeutic Candidate Targeting Coronavirus
SOUTH SAN FRANCISCO, Calif. and LEUVEN, Belgium, July 01, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a private biotechnology company focused on the development of targeted antiviral therapies directed against chronic hepatitis B (CHB), COVID-19 and therapeutics
Read more →ALGSAligos Therapeutics and Emory University Announce Expanded License Agreement and Ink Agreement for Chronic Hepatitis B Collaboration
SOUTH SAN FRANCISCO, Calif. and ATLANTA, June 23, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a private biotechnology company focused on the development of antiviral therapies targeting chronic hepatitis B (CHB) and COVID-19 as well as therapeutics for NASH, anno
Read more →ALGSAligos Therapeutics Submits Clinical Trial Application for Chronic Hepatitis B Oligonucleotide Candidate ALG-010133
SOUTH SAN FRANCISCO, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a private biotechnology company focused on the development of targeted antiviral therapies directed against chronic hepatitis B (CHB) and COVID-19 and therapeutics for NASH, today a
Read more →ALGSAligos Therapeutics Appoints Lesley Ann Calhoun as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a private biotechnology company focused on the development of targeted, antiviral therapies including chronic hepatitis B (CHB) and COVID-19 as well as therapeutics for NASH, today
Read more →ALGSAligos Therapeutics Expands Licensing Agreement with Luxna Biotech in Oligonucleotide Technology to Include Novel Coronavirus Targets
SOUTH SAN FRANCISCO, Calif., April 15, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc., a preclinical stage biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic s
Read more →ALGSAligos Therapeutics Closes $125M Series B Financing
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc., a preclinical stage biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic st
Read more →ALGSAligos Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, a pre-clinical stage biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatoh
Read more →ALGSAligos Therapeutics Presents Combination-Based Approach for Treating Chronic Hepatitis B (CHB) at HEP DART 2019
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Aligos Therapeutics, a pre-clinical stage biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatoh
Read more →ALGSAligos Therapeutics Welcomes Kathleen Sereda Glaub to its Board of Directors
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepat
Read more →ALGSAligos Therapeutics Presents NASH Asset Development Update at The Liver Meeting 2019
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a pre-clinical stage biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonal
Read more →ALGSAligos Therapeutics Presents Strong Chronic Hepatitis B Drug Candidate Portfolio at The Liver Meeting 2019
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a pre-clinical stage biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonal
Read more →ALGSAligos Therapeutics to Present Multiple Posters During The Liver Meeting 2019
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a pre-clinical stage biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonal
Read more →ALGSAligos Therapeutics Appoints Industry Veteran Matthew W. McClure, M.D., as Executive Vice President, Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a pre-clinical stage biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonal
Read more →Competitive Position
How ALGS ranks across every disease it competes inCompetitive Position is a premium feature
See how ALGS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial